IL-13对成纤维细胞胶原蛋白合成的影响及其分子调控机制
|
摘要
目的和意义
增生性瘢痕或瘢痕疙瘩是一种皮肤纤维化过程,可限制活动,影响皮肤的美观和功能,是皮肤组织烧伤、创伤修复后,由于全身和局部因素的影响,导致细胞外基质(ECM)过度分泌沉积、大量纤维组织增生、胶原降解减少、血管大量生成,包括成纤维细胞在内的组织修复细胞异常增殖分化而形成的。在纤维化的起始阶段,各种始动因素促使多种细胞因子的释放。细胞因子网络在介导炎症及其后的纤维化过程中所起的作用日益受到重视。有研究表明,在纤维化形成过程中存在1型辅助性T细胞(Th1)和2型辅助性T细胞(Th2)细胞因子间的失衡,即Th1/Th2失衡,从而促进了成纤维细胞激活、增生,细胞外基质沉积。Th1型细胞因子包括IFN-γ、IL-2、IL-12、IL-18和肿瘤坏死因子-β(TNF-β),Th2型细胞因子包括IL-4、IL-5、IL-10、IL-13和单核细胞趋化蛋白-1(MCP-1)。Th1型和Th2型细胞因子应答在纤维化方面的相反效应(即Th1型细胞因子的抗纤维化效应和Th2型细胞因子的促纤维化效应)已被近来的基因芯片技术所证实。白细胞介素13(IL-13)是一种多效能的免疫调节性细胞因子,主要由激活的辅助T淋巴细胞(Th2)产生,是许多由II类细胞因子决定的病理过程的关键诱导物。它能调节炎症、黏液产生、组织重建和纤维化,它在皮肤纤维化、肺纤维化、肝纤维化等多种纤维化疾病的发生机制中起重要作用,也是多种纤维化疾病的重要治疗靶点。为研究IL-13在瘢痕形成过程中的潜在作用,本研究探讨IL-13对瘢痕成纤维细胞的胶原合成作用及信号转导途径,观察IL-13是否促进瘢痕成纤维细胞胶原基因的转录和胶原蛋白的合成,这一过程是否通过IL-13结合瘢痕成纤维细胞膜上的IL-13受体,从而激活JAK/STAT信号转导通路,将胞内信号转导和转录激活因子STAT6蛋白磷酸化,后转入核内与胶原靶基因结合,上调胶原基因的转录,促进胶原蛋白的合成。另外观察酪氨酸酶抑制剂来氟米特A77 1726和抗纤维化药物干扰素-γ是否阻断IL-13的促瘢痕成纤维细胞的胶原合成作用,从而为IL-13纤维化机制的研究和瘢痕发生机制的研究增添新内容,同时为新方法用于临床瘢痕治疗奠定理论基础和提供实验依据。
研究内容和方法
1.IL-13对成纤维细胞的胶原合成作用的影响:体外培养成纤维细胞,绘制细胞生长曲线观察细胞生长状态。细胞分为实验组和对照组,实验组加入IL-13(100μg/L),对照组不加细胞因子,HE染色观察细胞形态,胶原纤维的特殊染色观察胶原纤维的形成,MTT法观察不同浓度的IL-13对成纤维细胞增殖作用的影响。IL-13细胞分为实验组和对照组,实验组加入IL-13(100μg/L),作用24、48、72小时后,绘制细胞生长曲线观察细胞生长状态,HE染色观察细胞形态,胶原纤维的特殊染色观察胶原纤维的形成,MTT法观察IL-13对成纤维细胞增殖作用的影响,羟脯氨酸检测IL-13对成纤维细胞分泌胶原蛋白的影响,RT-PCR观察IL-13对成纤维细胞I型胶原α1基因(Type I procollagen alpha 1,COL1A1)mRNA水平表达的影响,Western-Blotting观察IL-13对成纤维细胞分泌I型胶原蛋白的影响。
2.IL-13对成纤维细胞作用的信号转导通路的研究:RT-PCR检测成纤维细胞IL-13受体α1的表达,Western-Blotting观察IL-13作用成纤维细胞1、2、4、8小时后转录因子STAT6磷酸化蛋白及非磷酸化蛋白的表达。
3.酪氨酸酶抑制剂来氟米特A77 1726阻断IL-13对成纤维细胞的促胶原蛋白合成作用:MTT法观察不同浓度的A77 1726对成纤维细胞的增殖作用的影响。成纤维细胞分为实验组和实验对照组,实验对照组加入IL-13(100μg/L),实验组加入来氟米特A77 1726(50μM)和IL-13(100μg/L),作用24、48、72小时后,MTT法观察来氟米特对成纤维细胞的增殖作用的影响,羟脯氨酸检测来氟米特A77 1726对IL-13促进成纤维细胞分泌胶原蛋白的影响,RT-PCR观察来氟米特A77 1726对IL-13促进成纤维细胞I型胶原α1基因mRNA水平表达的影响, Western-Blotting观察来氟米特A77 1726对IL-13促进成纤维细胞分泌I型胶原蛋白的影响。
4.干扰素-γ抑制IL-13对成纤维细胞的促胶原蛋白合成作用:MTT法观察不同浓度的干扰素-γ对成纤维细胞的增殖作用的影响。成纤维细胞分为实验组和空白对照组,实验组加入干扰素-γ(4×105U/L)和IL-13(100μg/L),作用24、48、72小时后,羟脯氨酸检测干扰素-γ是否抑制IL-13促进成纤维细胞分泌胶原蛋白,RT-PCR观察干扰素-γ是否抑制IL-13促进成纤维细胞I型胶原α1基因mRNA水平的表达, Western-Blotting观察干扰素-γ是否抑制IL-13促进成纤维细胞分泌I型胶原蛋白。
结果
1.IL-13促进成纤维细胞的胶原合成作用:HE染色观察到实验组细胞增长旺盛,有明显的交叉重叠现象,胞浆丰富,但大体形态与对照组细胞无明显差别;胶原纤维特殊染色观察到实验组胶原纤维合成增加;MTT法观察到IL-13呈剂量依赖方式促进瘢痕成纤维细胞增殖;羟脯氨酸检测实验组细胞培养上清液分泌总胶原蛋白含量在IL-13作用48h、72h后显著高于对照组(P<0.05);RT-PCR检测到成纤维细胞表达I型胶原α1基因,且IL-13作用48h、72h后,表达显著增强(P<0.05);Western Blotting检测到成纤维细胞表达I型胶原蛋白,且IL-13作用48h、72h后,表达显著增强(P<0.05)。
2.IL-13介导成纤维细胞STAT6磷酸化:RT-PCR检测到成纤维细胞表达IL-13受体α1,Western-Blotting观察IL-13作用成纤维细胞1、2、4、8小时后均有非磷酸化STAT6蛋白的表达,IL-13作用2h后磷酸化STAT6蛋白表达最强(P<0.05),4h后衰减。
3.酪氨酸酶抑制剂来氟米特A77 1726阻断IL-13对成纤维细胞的促胶原蛋白合成作用:MTT法观察到来氟米特A77 172650μM的浓度可显著抑制成纤维细胞的增殖(P<0.05),羟脯氨酸检测实验组48h组和72h组成纤维细胞分泌胶原蛋白的含量显著低于实验对照组(P<0.05),RT-PCR观察到实验组48h组和72h组成纤维细胞I型胶原α1基因mRNA表达水平显著低于实验对照组(P<0.05),Western-Blotting观察到实验组48h组和72h组成纤维细胞分泌I型胶原蛋白的水平显著低于空白对照组(P<0.05)。
4.干扰素-γ抑制IL-13对成纤维细胞的促胶原蛋白合成作用:MTT法观察到干扰素-γ来氟米特50μM的浓度可显著抑制成纤维细胞的增殖(P<0.05),羟脯氨酸检测各时间段实验组48h组和72h组成纤维细胞分泌胶原蛋白的含量显著低于空白对照组(P<0.05),RT-PCR观察到各时间段实验组48h组和72h组成纤维细胞I型胶原α1基因mRNA表达水平显著低于空白对照组(P<0.05),Western-Blotting观察到各时间段实验组48h组和72h组成纤维细胞分泌I型胶原蛋白的水平显著低于空白对照组(P<0.05)。
结论
IL-13促进成纤维细胞的增殖,IL-13促进成纤维细胞分泌胶原,IL-13促进成纤维细胞I型胶原α1基因mRNA水平和蛋白水平的表达。成纤维细胞表达IL-13受体α1,IL-13作用成纤维细胞2小时后转录因子STAT6磷酸化蛋白的表达增强。酪氨酸酶抑制剂来氟米特A77 1726阻断IL-13对成纤维细胞的促增殖作用,阻断IL-13对成纤维细胞的促胶原蛋白合成作用,阻断IL-13促成纤维细胞I型胶原α1基因mRNA水平和蛋白水平的表达。干扰素-γ抑制IL-13对成纤维细胞的促胶原蛋白合成作用。
Objective and significance
Hypertrophic scar (HSc) and keloids are frequent and severe form of fibrosis of the skin, which limits movement and compromises the cosmetic appearance and function of the skin. Following severe skin injuries such as burns, hypertrophic scar (HSc) and keloids are frequent and severe form of fibrosis of the skin, which limits movement and compromises the cosmetic appearance and function of the skin. hypertrophic scar and keloids are formed, which are After is the skin organization burns, the wound repair, as a result of the whole body and the partial factor influence, from the deposition of causesexcessive extracellular matrix (ECM) to secrete the deposition, the proliferation of massive fiber structuretissues proliferation, the excessively reduction of collagen degeneration excessively reduces, the massive productions of blood vessels massive productions and , the proliferation and differentiation of repairs the cell including fibroblasts organization exceptionally to multiply the differentiation to formbecause of the whole body and the partial factors. In the initial fibrosis outset stage, each kind ofdifferent factors urges stimulate many kinds of cytokine the to release. Increasing evidences indicate that the cytokine network plays central role The role which the cytokine network in lies between leads in the inflammation and after thatthe in the fibrosis process plays to receive day by day takes. Some researches indicate that, there ishas imbalance between T helper type 1 lymphocyte in the fibrosis forming process (Th1) cytokine and T helper type 21 lymphocyte (Th2) cytokine imbalancein the fibrosis forming process, which was namely named the Th1/Th2 immunity is unbalanced., thus It promoted the activation and proliferation of to become the fibroblasts to activate, the proliferation,and the deposition of extracellular matrix deposition. The Th1 cytokines including include IFN-γ, IL-2, IL-12, IL-18 and the tumor necrosis factor - beta (TNF-β), the Th2 cytokines including include IL-4, IL-5, IL-10, IL-13 and monocyte chemotaxin protein - 1(MCP-1). .Th1 and the Th2 cytokine reply (i.e. Th1 cytokine anti-fibrosis effect and Th2 cytokine presses fibrosis effect) in the fibrosis aspect The opposing effects of Th1- and Th2- cytokine (i.e. the anti-fibrosis effect of Th1 cytokine and the fibrosis effect of Th2 cytokine) responses in fibrosis have also been substantiated by recent microarray experiments. Interleukine-13(IL-13) is a pleiotropic immune regulatory cytokine and a novel lymphokine produced by activated Type 2 helper cells. Interleukin (IL)-13 is a key inducer of several type-2 cytokine-dependent pathologies. It regulates inflammation, mucus production, tissue remodeling, and fibrosis. Consequently, IL-13 has been implicated in the pathogenesis of various diseases characterized by fibrosis, including skin fibrosis, liver fibrosis and idiopathic pulmonary fibrosis, and it become an important therapeutic target for a number of diseases in which IL-13 is believed to be overproduced. ForTo will understand well the latent function of IL-13 in in the scar forming process latent function, this research we have observed the effects of IL-13 on the scar to become the fibroblast collagen gene the duplicationtranscription ,the collagen generation and the signaling transduction pathway in the fibroblasts in in vitroraise waywill discuss IL-13 to become the fibroblast to the scar the collagen resultant action mechanism and the signal extension leads the way, will observe IL-13 will scar to become the fibroblast the duplicationwhetherthis process will become in the textile fiber cell membrane through the IL-13 union scar the IL-13 acceptor thus will extension to lead the circuit., We have detected the phosphorylation of STAT6 (signal extension will lead the butchetransducer and activator of transcription r in and copies the activation factor 6) STAT6 protein phosphorylationin response to IL-13., latter willchange overto traunion upward duplicationthe ionMoreover, the observation we have study tyrosine kinasestyrosinase inhibitor leflunomideA77 1726 and and the anti-fibrosis medicine interferon - gamma whether blocks the collagen generation induced by IL-13 to press the scar to becomein the fibroblastfibroblasts. the collagen resultant action, thus The study iswill shed new light on the mechanism of keloid and fibrosis mechanism. As a result, it provides new insight forthe IL-13 fibrosis mechanism research and the scar has the mechanism research to increase the new content, simultaneously uses in the the clinical scar keloid treatment for the new method laying the rationale and providing the experiment to rest on.
Research content and method
1.I The effect of IL-13 on the collagen generation in to becomes the fibroblasts the collagen generation influence: In vitro culture the The fibroblasts, the cell were divideds into the treatedexperimental group(added with 100μg/L IL-13) and the control group. after affects 24, 48, 72 hours, The cell growth condition was observed by the method of cell growth curve, and the cellular morphology was observed the by HE staining and the collagen fiber special staining were used to observe cellular morphology,. The cell fiber formation between fibroblasts was microscope observesd between the fibroblast cell andby the collagen fiber special staining the cell fiber formation,. the The activity of proliferation rate of fibroblasts with different concentration of IL-13in both groups was investigated and compared by MTT method. After 24, 48 and 72 hours in treated group, the total collagen content of the culture supernatant, was measured by Hydroxyproline(Hyp) release assay. The expression level of collagen Type I alpha 1 gene (COL1A1) mRNA in fibroblast was determined by the hydroxyproline examines IL-13 to become the fibroblast secretion collagen the influence, RT-PCR observes IL-13 to become the fibroblast Type I collagenα1 gene (Type I procollagen alpha 1, COL1A1) the mRNA level expression influence,, the level of collagen type I protein induced by IL-13 was analyzed by WWestern-Blotting was used to analyze the level of collagen type I induced by IL-13 in fibroblast. 2. The research of the signaling transduction pathway of IL-13 to becomesin the fibroblastfibroblasts function the signaling transduction pathway to lead the circuit the research: The expression of IL-13 receptorα1RT-PCR was examines examined by the fibroblast RT-PCR in fibroblastsIL-13 acceptorα1 expression. In addition, phosphorylation protein and the non-phosphorylation protein of transcription factor STAT6 were dectected in the treated group by Western-Blotting , after Western-blotting observes IL-13 to affect the fibroblastfibroblasts was induced by IL-13 for 1, 2, 4 and 8 hours1, 2, 4, 8 hours transcription factor STAT6 phosphorylation protein and the non-phosphorylation protein expression situation. 3. Tyrosine kinases inhibitor leflunomideA77 1726 to blockinhibites the collagen generation in fibroblasts induced by IL-13 to become the fibroblast to press the collagen resultant action: The inhibition rate of fibroblast proliferation with different concentration of A77 1726 was observed by MTT means. Becomes tThe fibroblasts were to divided into the experimental group(A77 1726 50μM and IL-13 100μg/L) and the experimental control group(IL-13 100μg/L).experimental joins sleflunomide, aAfter affects 24, 48 and 72 hours, the MTT means observes leflunomide to promote the fibroblast proliferation influence to IL-13, the inhibition effects of A77 1726 on collagen secretion of fibroblasts investigated the by hydroxyproline release assayto examine leflunomide to promote the fibroblast. The inhibition effects of A77 1726 on collagen type Iα1 gene mRNA expression in fibroblasts secretion collagen influence to IL-13, RT-PCR were to examinated leflunomide to promote the fibroblast type I collagenα1 gene mRNA level expression by RT-PCRinfluence to IL-13., The influence of A77 1726 on collagen type I synthesis in fibroblasts was analyzed Western-blotting to observe leflunomide influence IL-13 to promote the fibroblast to secrete type I collagenby Western-Blotting.
4. Interferons - gamma suppress collagen protein synthesis in fibroblasts induced by IL-13:to become the fibroblast the fibrosis function The inhibition rate of fibroblast proliferation with different concentration of interferon–γwas observed by MTT means. The fibroblasts were divided into the experimental group(interferon–γ4×105U/L and IL-13 100μg/L) and the control group. After 24, 48 and 72 hours, the inhibition effects of interferon–γon collagen secretion of fibroblasts were investigated by hydroxyproline release assay. The inhibition effects of interferon–γon collagen type Iα1 gene mRNA expression in fibroblasts induced by IL-13 were examinated by RT-PCR. The influence of interferon–γon collagen type I synthesis in fibroblasts induced by IL-13 was analyzed by Western-Blotting.Becomes the fibroblast to divide into the experimental group and the blank control group, the experimental group joins the interferon–γ4×105U/L and IL-13 (100μg/L), after affects 24, 48, 72 hours, hydroxyproline examination interferon - gamma whether suppresses IL-13 to promote the fibroblast secretion collagen, RT-PCR observation interferon - gamma whether suppresses IL-13 to promote the fibroblast type I collagenα1 gene mRNA level expression, Western-blotting observation interferon - gamma whether suppresses IL-13 to promote the fibroblast to secrete type I collagen.
Results
1. The effect of IL-13 on the collagen generation: IL-13 to becomes the fibroblast the collagen resultant action influence: The rapid growth of fibroblasts, the arrangement multipolarization, the obvious overlap phenomenon, as well as richer cytoplasma were found in the treated group by HE staining observes the experimental group cell growth to be exuberant, the arrangement multipolarization, has the obvious overlap phenomenon, the cytoplasma is alternately richer, but in the treated group roughly the cell shape is roughly the same as in and the control group cell not obvious difference,. the The more collagen fibers were observed in the experimental group by collagen fiber special staining microscope observes the experimental group cell collagen fiber synthesis to increase,. The proliferation rate of fibroblasts treated with IL-13 were increased obviously. the hydroxyproline examination experimental group cell raise supernate secretes the The total collagen secretion from fibroblasts induced by IL-13 for 48h or 72h was content obviously to be higher than that of the control group by hydroxyproline release assay (P<0.05); RT-PCR examines becomes the fibroblast to The expression of collagen type I collagenα1 gene in fibroblasts treated with IL-13 for 48h or 72h were increased significantly, compared with the control by RT-PCR after also IL-13 affects 24h, 48h, 72h, the expression strengthens (P<0.05); The expression of collagen type I protein in fibroblasts treated with IL-13 for 48h or 72h were also increased significantly, compared with the control by Western Blotting (P<0.05)Western blotting examines becomes the fibroblast to express I collagen, after also IL-13 affects 24h, 48h, 72h, the expression strengthens (P<0.05).
2. IL-13 induces the phosphorylation of STAT6 inIL-13 to becomes the fibroblastfibroblasts function the signaling transduction pathway to lead the circuit the research: RT-PCR examines The expression of IL-13 receptorα1mRNA was detected inbecomes the fibroblastfibroblasts by RT-PCR.to express the IL-13 acceptorα1, The expression of non-phosphorylation STAT6 protein was detected after Western-blotting observes IL-13 to affectafter the fibroblastfibroblasts were induced by IL-13 for 0, 1, 2, 4 and 8 hours by Western-Blotting has the non-phosphorylation STAT6 protein expression, and the expression of phosphorylation STAT6 protein was stronger after IL-13 affects in 2h the phosphorylation STAT6 protein expression to be strongest, and became weaker after 4h weakens.
3. Tyrosine kinases inhibitor A77 1726 inhibites the collagen generation in fibroblasts induced by IL-13: 3. Tyrosine kinases inhibitor leflunomide to block IL-13 to become the fibroblast to press the collagen resultant action: The proliferation of The fibroblasts was inhibited by A77 1726 MTT means observes the experiment to compose the fibroblast the proliferation obviously to be lower than the experimental control groupusing MTT means (P<0.05),. Total collagen generation was down-regulated after 48h or 72h stimulation of A77 1726 the hydroxyproline examines various time section experiment to compose the fibroblast secretion collagen the content obviously to be lower than the experimental control group by hydroxyproline release assay (P<0.05). The expression level of collagen type Iα1 gene mRNA was obviously lower in the experimental group than in the control group after 48h or 72h stimulation of A77 1726 by RT-PCR (P<0.05), RT-PCR observes various time section experiment to compose the fibroblast type I collagenα1 gene mRNA expression level obviously to be lower than the experimental control group (P<0.05). C, ollagen type I production of fibroblasts treated with A77 1726 for 48 and 72 hours was decreased obviously in the experimental group than in the control group byW Western-Blotting observes various time section experiment to compose the fibroblast to secrete type I collagen the level obviously to be lower than the blank control group (P<0.05).
4. Interferons - gamma suppress collagen protein synthesis in fibroblasts induced by IL-13: The proliferation of fibroblasts was inhibited by interferon - gamma by MTT means. Total collagen generation was down-regulated of fibroblasts treated with interferon - gamma for 48h or 72h by hydroxyproline release assay (P<0.05). The expression level of collagen type Iα1 gene mRNA was obviously lower in the experimental group than in the control group after 48 or 72hours stimulation of interferon - gamma by RT-PCR (P<0.05). Collagen type I production of fibroblasts treated with interferon - gamma in 48 or 72 hours was decreased obviously in the experimental group than in the control group by Western-Blotting (P<0.05).
4. Interferon-γsuppresses IL-13 to become the fibroblast the fibrosis function: The hydroxyproline examines various time section experiment to compose the fibroblast secretion collagen the content obviously to be lower than the blank control group (P<0.05), RT-PCR observes various time section experiment to compose the fibroblast type I collagenα1 gene mRNA expression level obviously to be lower than the blank control group (P<0.05), Western-blotting observes various time section experiment to compose the fibroblast to secrete type I collagen the level obviously to be lower than the blank control group (P<0.05).
Conclusion
IL-13 may promote promotes the proliferation of the fibroblastfibroblasts proliferation, to be possible to increases the total collagen generation promoteof the fibroblastfibroblasts secretion collagen content, upregulates to be possible to promotethe expression of mRNA and protein of collagen type Iα1 gene the fibroblast I collagenα1 gene mRNA level and the protein level expression. IL-13 receptorα1 was expressed in human keloid fibroblastBecomes the fibroblast to express the IL-13 acceptorα1., The expression of phosphorylated STAT6 protein was strongest in fibroblasts after stimulation with IL-13 for 2h. after also IL-13 affects the fibroblast for 2 hours to transcription factor STAT6 phosphorylation protein the expression enhancement. Tyrosine kinases inhibitor leflunomideA77 1726 has the inhibitory effect on proliferation and total collagen generation induced in fibroblasts by IL-13to be possible to block IL-13 to become the fibroblast to proliferation function, it also blocks decreasedIL-13 to become the fibroblast to press the collagen resultant action, blocks IL-13 to facilitate the expression of c the fibroblastollagen type I collagenα1 gene mRNA level and collagen type I the protein level expressionin fibroblasts induced by IL-13. The interferon - gamma may suppresshas the inhibitory effect on collagen protein synthesis in fibroblasts induced by IL-13to become the fibroblast the fibrosis function.
增生性瘢痕或瘢痕疙瘩是一种皮肤纤维化过程,可限制活动,影响皮肤的美观和功能,是皮肤组织烧伤、创伤修复后,由于全身和局部因素的影响,导致细胞外基质(ECM)过度分泌沉积、大量纤维组织增生、胶原降解减少、血管大量生成,包括成纤维细胞在内的组织修复细胞异常增殖分化而形成的。在纤维化的起始阶段,各种始动因素促使多种细胞因子的释放。细胞因子网络在介导炎症及其后的纤维化过程中所起的作用日益受到重视。有研究表明,在纤维化形成过程中存在1型辅助性T细胞(Th1)和2型辅助性T细胞(Th2)细胞因子间的失衡,即Th1/Th2失衡,从而促进了成纤维细胞激活、增生,细胞外基质沉积。Th1型细胞因子包括IFN-γ、IL-2、IL-12、IL-18和肿瘤坏死因子-β(TNF-β),Th2型细胞因子包括IL-4、IL-5、IL-10、IL-13和单核细胞趋化蛋白-1(MCP-1)。Th1型和Th2型细胞因子应答在纤维化方面的相反效应(即Th1型细胞因子的抗纤维化效应和Th2型细胞因子的促纤维化效应)已被近来的基因芯片技术所证实。白细胞介素13(IL-13)是一种多效能的免疫调节性细胞因子,主要由激活的辅助T淋巴细胞(Th2)产生,是许多由II类细胞因子决定的病理过程的关键诱导物。它能调节炎症、黏液产生、组织重建和纤维化,它在皮肤纤维化、肺纤维化、肝纤维化等多种纤维化疾病的发生机制中起重要作用,也是多种纤维化疾病的重要治疗靶点。为研究IL-13在瘢痕形成过程中的潜在作用,本研究探讨IL-13对瘢痕成纤维细胞的胶原合成作用及信号转导途径,观察IL-13是否促进瘢痕成纤维细胞胶原基因的转录和胶原蛋白的合成,这一过程是否通过IL-13结合瘢痕成纤维细胞膜上的IL-13受体,从而激活JAK/STAT信号转导通路,将胞内信号转导和转录激活因子STAT6蛋白磷酸化,后转入核内与胶原靶基因结合,上调胶原基因的转录,促进胶原蛋白的合成。另外观察酪氨酸酶抑制剂来氟米特A77 1726和抗纤维化药物干扰素-γ是否阻断IL-13的促瘢痕成纤维细胞的胶原合成作用,从而为IL-13纤维化机制的研究和瘢痕发生机制的研究增添新内容,同时为新方法用于临床瘢痕治疗奠定理论基础和提供实验依据。
研究内容和方法
1.IL-13对成纤维细胞的胶原合成作用的影响:体外培养成纤维细胞,绘制细胞生长曲线观察细胞生长状态。细胞分为实验组和对照组,实验组加入IL-13(100μg/L),对照组不加细胞因子,HE染色观察细胞形态,胶原纤维的特殊染色观察胶原纤维的形成,MTT法观察不同浓度的IL-13对成纤维细胞增殖作用的影响。IL-13细胞分为实验组和对照组,实验组加入IL-13(100μg/L),作用24、48、72小时后,绘制细胞生长曲线观察细胞生长状态,HE染色观察细胞形态,胶原纤维的特殊染色观察胶原纤维的形成,MTT法观察IL-13对成纤维细胞增殖作用的影响,羟脯氨酸检测IL-13对成纤维细胞分泌胶原蛋白的影响,RT-PCR观察IL-13对成纤维细胞I型胶原α1基因(Type I procollagen alpha 1,COL1A1)mRNA水平表达的影响,Western-Blotting观察IL-13对成纤维细胞分泌I型胶原蛋白的影响。
2.IL-13对成纤维细胞作用的信号转导通路的研究:RT-PCR检测成纤维细胞IL-13受体α1的表达,Western-Blotting观察IL-13作用成纤维细胞1、2、4、8小时后转录因子STAT6磷酸化蛋白及非磷酸化蛋白的表达。
3.酪氨酸酶抑制剂来氟米特A77 1726阻断IL-13对成纤维细胞的促胶原蛋白合成作用:MTT法观察不同浓度的A77 1726对成纤维细胞的增殖作用的影响。成纤维细胞分为实验组和实验对照组,实验对照组加入IL-13(100μg/L),实验组加入来氟米特A77 1726(50μM)和IL-13(100μg/L),作用24、48、72小时后,MTT法观察来氟米特对成纤维细胞的增殖作用的影响,羟脯氨酸检测来氟米特A77 1726对IL-13促进成纤维细胞分泌胶原蛋白的影响,RT-PCR观察来氟米特A77 1726对IL-13促进成纤维细胞I型胶原α1基因mRNA水平表达的影响, Western-Blotting观察来氟米特A77 1726对IL-13促进成纤维细胞分泌I型胶原蛋白的影响。
4.干扰素-γ抑制IL-13对成纤维细胞的促胶原蛋白合成作用:MTT法观察不同浓度的干扰素-γ对成纤维细胞的增殖作用的影响。成纤维细胞分为实验组和空白对照组,实验组加入干扰素-γ(4×105U/L)和IL-13(100μg/L),作用24、48、72小时后,羟脯氨酸检测干扰素-γ是否抑制IL-13促进成纤维细胞分泌胶原蛋白,RT-PCR观察干扰素-γ是否抑制IL-13促进成纤维细胞I型胶原α1基因mRNA水平的表达, Western-Blotting观察干扰素-γ是否抑制IL-13促进成纤维细胞分泌I型胶原蛋白。
结果
1.IL-13促进成纤维细胞的胶原合成作用:HE染色观察到实验组细胞增长旺盛,有明显的交叉重叠现象,胞浆丰富,但大体形态与对照组细胞无明显差别;胶原纤维特殊染色观察到实验组胶原纤维合成增加;MTT法观察到IL-13呈剂量依赖方式促进瘢痕成纤维细胞增殖;羟脯氨酸检测实验组细胞培养上清液分泌总胶原蛋白含量在IL-13作用48h、72h后显著高于对照组(P<0.05);RT-PCR检测到成纤维细胞表达I型胶原α1基因,且IL-13作用48h、72h后,表达显著增强(P<0.05);Western Blotting检测到成纤维细胞表达I型胶原蛋白,且IL-13作用48h、72h后,表达显著增强(P<0.05)。
2.IL-13介导成纤维细胞STAT6磷酸化:RT-PCR检测到成纤维细胞表达IL-13受体α1,Western-Blotting观察IL-13作用成纤维细胞1、2、4、8小时后均有非磷酸化STAT6蛋白的表达,IL-13作用2h后磷酸化STAT6蛋白表达最强(P<0.05),4h后衰减。
3.酪氨酸酶抑制剂来氟米特A77 1726阻断IL-13对成纤维细胞的促胶原蛋白合成作用:MTT法观察到来氟米特A77 172650μM的浓度可显著抑制成纤维细胞的增殖(P<0.05),羟脯氨酸检测实验组48h组和72h组成纤维细胞分泌胶原蛋白的含量显著低于实验对照组(P<0.05),RT-PCR观察到实验组48h组和72h组成纤维细胞I型胶原α1基因mRNA表达水平显著低于实验对照组(P<0.05),Western-Blotting观察到实验组48h组和72h组成纤维细胞分泌I型胶原蛋白的水平显著低于空白对照组(P<0.05)。
4.干扰素-γ抑制IL-13对成纤维细胞的促胶原蛋白合成作用:MTT法观察到干扰素-γ来氟米特50μM的浓度可显著抑制成纤维细胞的增殖(P<0.05),羟脯氨酸检测各时间段实验组48h组和72h组成纤维细胞分泌胶原蛋白的含量显著低于空白对照组(P<0.05),RT-PCR观察到各时间段实验组48h组和72h组成纤维细胞I型胶原α1基因mRNA表达水平显著低于空白对照组(P<0.05),Western-Blotting观察到各时间段实验组48h组和72h组成纤维细胞分泌I型胶原蛋白的水平显著低于空白对照组(P<0.05)。
结论
IL-13促进成纤维细胞的增殖,IL-13促进成纤维细胞分泌胶原,IL-13促进成纤维细胞I型胶原α1基因mRNA水平和蛋白水平的表达。成纤维细胞表达IL-13受体α1,IL-13作用成纤维细胞2小时后转录因子STAT6磷酸化蛋白的表达增强。酪氨酸酶抑制剂来氟米特A77 1726阻断IL-13对成纤维细胞的促增殖作用,阻断IL-13对成纤维细胞的促胶原蛋白合成作用,阻断IL-13促成纤维细胞I型胶原α1基因mRNA水平和蛋白水平的表达。干扰素-γ抑制IL-13对成纤维细胞的促胶原蛋白合成作用。
Objective and significance
Hypertrophic scar (HSc) and keloids are frequent and severe form of fibrosis of the skin, which limits movement and compromises the cosmetic appearance and function of the skin. Following severe skin injuries such as burns, hypertrophic scar (HSc) and keloids are frequent and severe form of fibrosis of the skin, which limits movement and compromises the cosmetic appearance and function of the skin. hypertrophic scar and keloids are formed, which are After is the skin organization burns, the wound repair, as a result of the whole body and the partial factor influence, from the deposition of causesexcessive extracellular matrix (ECM) to secrete the deposition, the proliferation of massive fiber structuretissues proliferation, the excessively reduction of collagen degeneration excessively reduces, the massive productions of blood vessels massive productions and , the proliferation and differentiation of repairs the cell including fibroblasts organization exceptionally to multiply the differentiation to formbecause of the whole body and the partial factors. In the initial fibrosis outset stage, each kind ofdifferent factors urges stimulate many kinds of cytokine the to release. Increasing evidences indicate that the cytokine network plays central role The role which the cytokine network in lies between leads in the inflammation and after thatthe in the fibrosis process plays to receive day by day takes. Some researches indicate that, there ishas imbalance between T helper type 1 lymphocyte in the fibrosis forming process (Th1) cytokine and T helper type 21 lymphocyte (Th2) cytokine imbalancein the fibrosis forming process, which was namely named the Th1/Th2 immunity is unbalanced., thus It promoted the activation and proliferation of to become the fibroblasts to activate, the proliferation,and the deposition of extracellular matrix deposition. The Th1 cytokines including include IFN-γ, IL-2, IL-12, IL-18 and the tumor necrosis factor - beta (TNF-β), the Th2 cytokines including include IL-4, IL-5, IL-10, IL-13 and monocyte chemotaxin protein - 1(MCP-1). .Th1 and the Th2 cytokine reply (i.e. Th1 cytokine anti-fibrosis effect and Th2 cytokine presses fibrosis effect) in the fibrosis aspect The opposing effects of Th1- and Th2- cytokine (i.e. the anti-fibrosis effect of Th1 cytokine and the fibrosis effect of Th2 cytokine) responses in fibrosis have also been substantiated by recent microarray experiments. Interleukine-13(IL-13) is a pleiotropic immune regulatory cytokine and a novel lymphokine produced by activated Type 2 helper cells. Interleukin (IL)-13 is a key inducer of several type-2 cytokine-dependent pathologies. It regulates inflammation, mucus production, tissue remodeling, and fibrosis. Consequently, IL-13 has been implicated in the pathogenesis of various diseases characterized by fibrosis, including skin fibrosis, liver fibrosis and idiopathic pulmonary fibrosis, and it become an important therapeutic target for a number of diseases in which IL-13 is believed to be overproduced. ForTo will understand well the latent function of IL-13 in in the scar forming process latent function, this research we have observed the effects of IL-13 on the scar to become the fibroblast collagen gene the duplicationtranscription ,the collagen generation and the signaling transduction pathway in the fibroblasts in in vitroraise waywill discuss IL-13 to become the fibroblast to the scar the collagen resultant action mechanism and the signal extension leads the way, will observe IL-13 will scar to become the fibroblast the duplicationwhetherthis process will become in the textile fiber cell membrane through the IL-13 union scar the IL-13 acceptor thus will extension to lead the circuit., We have detected the phosphorylation of STAT6 (signal extension will lead the butchetransducer and activator of transcription r in and copies the activation factor 6) STAT6 protein phosphorylationin response to IL-13., latter willchange overto traunion upward duplicationthe ionMoreover, the observation we have study tyrosine kinasestyrosinase inhibitor leflunomideA77 1726 and and the anti-fibrosis medicine interferon - gamma whether blocks the collagen generation induced by IL-13 to press the scar to becomein the fibroblastfibroblasts. the collagen resultant action, thus The study iswill shed new light on the mechanism of keloid and fibrosis mechanism. As a result, it provides new insight forthe IL-13 fibrosis mechanism research and the scar has the mechanism research to increase the new content, simultaneously uses in the the clinical scar keloid treatment for the new method laying the rationale and providing the experiment to rest on.
Research content and method
1.I The effect of IL-13 on the collagen generation in to becomes the fibroblasts the collagen generation influence: In vitro culture the The fibroblasts, the cell were divideds into the treatedexperimental group(added with 100μg/L IL-13) and the control group. after affects 24, 48, 72 hours, The cell growth condition was observed by the method of cell growth curve, and the cellular morphology was observed the by HE staining and the collagen fiber special staining were used to observe cellular morphology,. The cell fiber formation between fibroblasts was microscope observesd between the fibroblast cell andby the collagen fiber special staining the cell fiber formation,. the The activity of proliferation rate of fibroblasts with different concentration of IL-13in both groups was investigated and compared by MTT method. After 24, 48 and 72 hours in treated group, the total collagen content of the culture supernatant, was measured by Hydroxyproline(Hyp) release assay. The expression level of collagen Type I alpha 1 gene (COL1A1) mRNA in fibroblast was determined by the hydroxyproline examines IL-13 to become the fibroblast secretion collagen the influence, RT-PCR observes IL-13 to become the fibroblast Type I collagenα1 gene (Type I procollagen alpha 1, COL1A1) the mRNA level expression influence,, the level of collagen type I protein induced by IL-13 was analyzed by WWestern-Blotting was used to analyze the level of collagen type I induced by IL-13 in fibroblast. 2. The research of the signaling transduction pathway of IL-13 to becomesin the fibroblastfibroblasts function the signaling transduction pathway to lead the circuit the research: The expression of IL-13 receptorα1RT-PCR was examines examined by the fibroblast RT-PCR in fibroblastsIL-13 acceptorα1 expression. In addition, phosphorylation protein and the non-phosphorylation protein of transcription factor STAT6 were dectected in the treated group by Western-Blotting , after Western-blotting observes IL-13 to affect the fibroblastfibroblasts was induced by IL-13 for 1, 2, 4 and 8 hours1, 2, 4, 8 hours transcription factor STAT6 phosphorylation protein and the non-phosphorylation protein expression situation. 3. Tyrosine kinases inhibitor leflunomideA77 1726 to blockinhibites the collagen generation in fibroblasts induced by IL-13 to become the fibroblast to press the collagen resultant action: The inhibition rate of fibroblast proliferation with different concentration of A77 1726 was observed by MTT means. Becomes tThe fibroblasts were to divided into the experimental group(A77 1726 50μM and IL-13 100μg/L) and the experimental control group(IL-13 100μg/L).experimental joins sleflunomide, aAfter affects 24, 48 and 72 hours, the MTT means observes leflunomide to promote the fibroblast proliferation influence to IL-13, the inhibition effects of A77 1726 on collagen secretion of fibroblasts investigated the by hydroxyproline release assayto examine leflunomide to promote the fibroblast. The inhibition effects of A77 1726 on collagen type Iα1 gene mRNA expression in fibroblasts secretion collagen influence to IL-13, RT-PCR were to examinated leflunomide to promote the fibroblast type I collagenα1 gene mRNA level expression by RT-PCRinfluence to IL-13., The influence of A77 1726 on collagen type I synthesis in fibroblasts was analyzed Western-blotting to observe leflunomide influence IL-13 to promote the fibroblast to secrete type I collagenby Western-Blotting.
4. Interferons - gamma suppress collagen protein synthesis in fibroblasts induced by IL-13:to become the fibroblast the fibrosis function The inhibition rate of fibroblast proliferation with different concentration of interferon–γwas observed by MTT means. The fibroblasts were divided into the experimental group(interferon–γ4×105U/L and IL-13 100μg/L) and the control group. After 24, 48 and 72 hours, the inhibition effects of interferon–γon collagen secretion of fibroblasts were investigated by hydroxyproline release assay. The inhibition effects of interferon–γon collagen type Iα1 gene mRNA expression in fibroblasts induced by IL-13 were examinated by RT-PCR. The influence of interferon–γon collagen type I synthesis in fibroblasts induced by IL-13 was analyzed by Western-Blotting.Becomes the fibroblast to divide into the experimental group and the blank control group, the experimental group joins the interferon–γ4×105U/L and IL-13 (100μg/L), after affects 24, 48, 72 hours, hydroxyproline examination interferon - gamma whether suppresses IL-13 to promote the fibroblast secretion collagen, RT-PCR observation interferon - gamma whether suppresses IL-13 to promote the fibroblast type I collagenα1 gene mRNA level expression, Western-blotting observation interferon - gamma whether suppresses IL-13 to promote the fibroblast to secrete type I collagen.
Results
1. The effect of IL-13 on the collagen generation: IL-13 to becomes the fibroblast the collagen resultant action influence: The rapid growth of fibroblasts, the arrangement multipolarization, the obvious overlap phenomenon, as well as richer cytoplasma were found in the treated group by HE staining observes the experimental group cell growth to be exuberant, the arrangement multipolarization, has the obvious overlap phenomenon, the cytoplasma is alternately richer, but in the treated group roughly the cell shape is roughly the same as in and the control group cell not obvious difference,. the The more collagen fibers were observed in the experimental group by collagen fiber special staining microscope observes the experimental group cell collagen fiber synthesis to increase,. The proliferation rate of fibroblasts treated with IL-13 were increased obviously. the hydroxyproline examination experimental group cell raise supernate secretes the The total collagen secretion from fibroblasts induced by IL-13 for 48h or 72h was content obviously to be higher than that of the control group by hydroxyproline release assay (P<0.05); RT-PCR examines becomes the fibroblast to The expression of collagen type I collagenα1 gene in fibroblasts treated with IL-13 for 48h or 72h were increased significantly, compared with the control by RT-PCR after also IL-13 affects 24h, 48h, 72h, the expression strengthens (P<0.05); The expression of collagen type I protein in fibroblasts treated with IL-13 for 48h or 72h were also increased significantly, compared with the control by Western Blotting (P<0.05)Western blotting examines becomes the fibroblast to express I collagen, after also IL-13 affects 24h, 48h, 72h, the expression strengthens (P<0.05).
2. IL-13 induces the phosphorylation of STAT6 inIL-13 to becomes the fibroblastfibroblasts function the signaling transduction pathway to lead the circuit the research: RT-PCR examines The expression of IL-13 receptorα1mRNA was detected inbecomes the fibroblastfibroblasts by RT-PCR.to express the IL-13 acceptorα1, The expression of non-phosphorylation STAT6 protein was detected after Western-blotting observes IL-13 to affectafter the fibroblastfibroblasts were induced by IL-13 for 0, 1, 2, 4 and 8 hours by Western-Blotting has the non-phosphorylation STAT6 protein expression, and the expression of phosphorylation STAT6 protein was stronger after IL-13 affects in 2h the phosphorylation STAT6 protein expression to be strongest, and became weaker after 4h weakens.
3. Tyrosine kinases inhibitor A77 1726 inhibites the collagen generation in fibroblasts induced by IL-13: 3. Tyrosine kinases inhibitor leflunomide to block IL-13 to become the fibroblast to press the collagen resultant action: The proliferation of The fibroblasts was inhibited by A77 1726 MTT means observes the experiment to compose the fibroblast the proliferation obviously to be lower than the experimental control groupusing MTT means (P<0.05),. Total collagen generation was down-regulated after 48h or 72h stimulation of A77 1726 the hydroxyproline examines various time section experiment to compose the fibroblast secretion collagen the content obviously to be lower than the experimental control group by hydroxyproline release assay (P<0.05). The expression level of collagen type Iα1 gene mRNA was obviously lower in the experimental group than in the control group after 48h or 72h stimulation of A77 1726 by RT-PCR (P<0.05), RT-PCR observes various time section experiment to compose the fibroblast type I collagenα1 gene mRNA expression level obviously to be lower than the experimental control group (P<0.05). C, ollagen type I production of fibroblasts treated with A77 1726 for 48 and 72 hours was decreased obviously in the experimental group than in the control group byW Western-Blotting observes various time section experiment to compose the fibroblast to secrete type I collagen the level obviously to be lower than the blank control group (P<0.05).
4. Interferons - gamma suppress collagen protein synthesis in fibroblasts induced by IL-13: The proliferation of fibroblasts was inhibited by interferon - gamma by MTT means. Total collagen generation was down-regulated of fibroblasts treated with interferon - gamma for 48h or 72h by hydroxyproline release assay (P<0.05). The expression level of collagen type Iα1 gene mRNA was obviously lower in the experimental group than in the control group after 48 or 72hours stimulation of interferon - gamma by RT-PCR (P<0.05). Collagen type I production of fibroblasts treated with interferon - gamma in 48 or 72 hours was decreased obviously in the experimental group than in the control group by Western-Blotting (P<0.05).
4. Interferon-γsuppresses IL-13 to become the fibroblast the fibrosis function: The hydroxyproline examines various time section experiment to compose the fibroblast secretion collagen the content obviously to be lower than the blank control group (P<0.05), RT-PCR observes various time section experiment to compose the fibroblast type I collagenα1 gene mRNA expression level obviously to be lower than the blank control group (P<0.05), Western-blotting observes various time section experiment to compose the fibroblast to secrete type I collagen the level obviously to be lower than the blank control group (P<0.05).
Conclusion
IL-13 may promote promotes the proliferation of the fibroblastfibroblasts proliferation, to be possible to increases the total collagen generation promoteof the fibroblastfibroblasts secretion collagen content, upregulates to be possible to promotethe expression of mRNA and protein of collagen type Iα1 gene the fibroblast I collagenα1 gene mRNA level and the protein level expression. IL-13 receptorα1 was expressed in human keloid fibroblastBecomes the fibroblast to express the IL-13 acceptorα1., The expression of phosphorylated STAT6 protein was strongest in fibroblasts after stimulation with IL-13 for 2h. after also IL-13 affects the fibroblast for 2 hours to transcription factor STAT6 phosphorylation protein the expression enhancement. Tyrosine kinases inhibitor leflunomideA77 1726 has the inhibitory effect on proliferation and total collagen generation induced in fibroblasts by IL-13to be possible to block IL-13 to become the fibroblast to proliferation function, it also blocks decreasedIL-13 to become the fibroblast to press the collagen resultant action, blocks IL-13 to facilitate the expression of c the fibroblastollagen type I collagenα1 gene mRNA level and collagen type I the protein level expressionin fibroblasts induced by IL-13. The interferon - gamma may suppresshas the inhibitory effect on collagen protein synthesis in fibroblasts induced by IL-13to become the fibroblast the fibrosis function.
引文
[1] Tan RJ, Fattman CL, Niehouse LM, et al. Matrix Metalloproteinases Promote Inflammation and Fibrosis in Asbestos-induced Lung Injury in Mice. Am J Respir Cell Mol Biol, 2006, Vol. 35(3): 289-297
[2] 高春芳,陆伦根. 纤维化疾病的基础和临床. 第一版. 上海: 上海科学技术出版社, 2004: 199-201
[3] Marneros AG, Krieg T. Keloids--clinical diagnosis, pathogenesis, and treatment options. J Dtsch Dermatol Ges, 2004, Vol. 2(11):905-913
[4] Slemp AE, Kirschner RE. Keloids and scars: a review of keloids and scars, their pathogenesis, risk factors, and management. Curr Opin Pediatr, 2006, Vol. 18(4): 396-402
[5] Ala-Kokko L, Rintala A, Savolainen ER. Collagen gene expression in keloids: analysis of collagen metabolism and type I, III, IV, and V procollagen mRNAs in keloid tissue and keloid fibroblast culture. J Invest Dermatol, 1987, Vol. 89(3): 238-244
[6] Abergel RP, Pizzurro D, Meeker CA, et al. Biochemical composition of the connective tissue in keloids and analysis of collagen metabolism in keloid fibroblasts cultures. J Invest Dermatol, 1985, Vol. 84(5): 384-390
[7] Wynn TA. Fibrotic disease and the TH1/ TH2 paradigm. Nat Rev Immunol, 2004, Vol. 4(8):583-594
[8] Gurujeyalakshmi G, Giri SN. Molecular mechanisms of antifibrotic effect of interferon-γ i?n bleomycin-mouse model of lung fibrosis: downregulation of TGF-β a?nd procollagen I and III gene expression. Exp Lung Res, 1995, Vol. 21(5): 791-808
[9] Cho JY, Miller M, Baek KJ, et al. Inhibition of airway remodeling in IL-5-deficient mice. J. Clin. Invest, 2004, Vol. 113(4): 551–560
[10] Huaux F, Liu T, Mcgarry B, et al. Eosinophils and T lymphocytes possess distinct roles in bleomycin-induced lung injury and fibrosis. J Immunol, 2003, Vol. 171(10): 5470–5481
[11] Nelson DR, Tu Z, Soldevila-Pico C, et al. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology, 2003, Vol. 38(4): 859–868
[12] Hesse M, Piccirillo CA, Belkaid Y, et al. The pathogenesis of schistosomiasis is controlled by cooperating IL-10-producing innate effector and regulatory T cells. J Immunol, 2004, Vol. 172(5): 3157–3166
[13] Lee CG, Homer RJ, Cohn L, et al. Transgenic overexpression of interleukin (IL)-10 in the lung causes mucus metaplasia tissue inflammation, and airway remodeling via IL-13-dependent and -independent pathways. J Biol Chem, 2002, Vol. 277(38): 35466–35474
[14] Hoffmann KF, McLarty TC, Seqal DH, et al. Disease fingerprinting with cDNA microarraysreveals distinct gene expression profiles in lethal type 1 and type 2 cytokine-mediated inflammatory reactions. FASEB J, 2001, Vol. 15(13): 2545-2547
[15] Sandler NG., Mentink-Kane MM., Cheever A, et al. Global gene expression profiles during acute pathogen-induced pulmonary inflammation reveal divergent roles for TH1 and TH2 responses in tissue repair. J Immunol, 2003, Vol. 171(7): 3655-36674
[16] Brazova J, Sediva A, Pospisilova D, et al. Differential cytokine profile in children with cystic fibrosis. Clin Immunol, 2005, Vol. 115(2):210-215
[17] Pacanowski MA, Amsden GW. Interferon Gamma-1b in the Treatment of Idiopathic Pulmonary Fibrosis (October). Ann Pharmacother. 2005, Vol. 39(10):1678-1686
[18] Oldroyd SD, Thomas GL, Gabbiani G, et al. Interferon-γ ?inhibits experimental renal fibrosis. Kidney Int, 1999, Vol. 56(6): 2116-2127
[19] Jordana M, Ohna I, Xing Z, et al. Cytokines in lung and airways fibrosis. Reg Immunol. 1993, Vol. 5(3-4):201-206
[20] Magalhaes A, Miranda DG, Miranda RG, et al. Cytokine profile associated with human chronic schistosomiasis mansoni. Mem Inst Oswaldo Cruz, 2004, Vol. 99(5 Suppl 1):21-26
[21] Keane MP, Belperio JA, Burdick MD, et al. IL-12 attenuates bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell. Mol. Physiol. 2001, Vol. 281(1): L92-L97
[22] Sempowski GD, Beckmann MP, Derdak S, et al. Subsets of murine lung fibroblasts express membrane-bound and soluble IL-4 receptors. Role of IL-4 in enhancing fibroblast proliferation and collagen synthesis. J Immunol, 1994, Vol. 152(7): 3606-3614
[23] Lee CG, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor β1. J Exp Med, 2001, Vol. 194(6): 809-821
[24] Sheppard D. Transforming growth factor beta: a central modulator of pulmonary and airway inflammation and fibrosis. Proc Am Thorac Soc, 2006, Vol. 3(5):413-417
[25] Roberts AB, Russo A, Felici A, et al. Smad3: a key player in pathogenetic mechanisms dependent on TGF-β. Ann NY Acad Sci, 2003, Vol. 995: 1–10
[26] Wang S, Hirschberg R. BMP7 antagonizes TGF-β-dependent fibrogenesis in mesangial cells. Am. J. Physiol. Renal Physiol, 2003, Vol. 284(5): F1006–F1013
[27] Ma LJ, Yang H, Gaspert A, et al. Transforming growth factor-β-dependent and -independent pathways of induction of tubulointerstitial fibrosis in β6–/– mice. Am. J. Pathol, 2003, Vol. 163(4):1261–1273
[28] Zhang T, Rong XZ, Yang RH, et al. Effect of asiaticoside on the expression of transforming growth factor-beta mRNA and matrix metalloproteinases in hypertrophic scars. Nan Fang Yi Ke Da Xue Xue Bao, 2006, Vol. 26(1):67-70
[29] Wynn T A. IL-13 effector functions. Annu Rev Immunol, 2003, Vol. 21: 425-456
[30] Brown KD, Zurawski SM, Mosmann TR, et al. A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes. J Immunol, 1989, Vol. 142(2): 679-687
[31] Minty A, Chalon P, Derocq JM, et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature, 1993, Vol. 362(6417): 248-250
[32] Mckenzie A N J, Culpepper J A, Walefyt R D, et al. Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc Natl Acad Sci USA, 1993, Vol. 90: 3735-3739
[33] Mentink-Kane MM, Cheever AW, Thompson RW, et al. IL-13 receptor α2 downmodulates granulomatous inflammation and prolongs host survival in schistosomiasis. Proc Natl Acad Sci USA, 2004, Vol. 101(2): 586-590
[34] Wood N, Whitters MJ, Jacobson BA, et al. Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor α2. Exp Med, 2003, Vol. 197(6): 703–709.
[35] Jakubzick C, Choi ES, Kunkel SL, et al. Impact of interleukin-13 responsiveness on the synthetic and proliferative properties of TH1- and TH2-type pulmonary granuloma fibroblasts. Am J Pathol, 2003, Vol. 162(5), 1475–1486
[36] Chiaramonte MG., Cheever AW, Malley JD, et al. Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis. Hepatology, 2001, Vol. 34(2): 273-282
[37] Jakubzick C, Kunkel SL, Puri RK, et al. Therapeutic targeting of IL-4- and IL-13-responsive cells in pulmonary fibrosis. Immunol Res, 2004, Vol. 30(3): 339-349
[38] Elias JA, Kang MJ, Crouthers K, et al. State of the art. Mechanistic heterogeneity in chronic obstructive pulmonary disease: insights from transgenic mice. Proc Am Thorac Soc. 2006, Vol. 3(6):494-498
[39] Fulkerson PC, Fischetti CA, Hassman LM, et al. Persistent effects induced by IL-13 in the lung. Am J Respir Cell Mol Biol. 2006, Vol. 35(3):337-346
[40] Jiang H, Harris MB, Rothman P. IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol. 2000, Vol. 105(6):1063-1070
[41] Kelly-Welch A, Hanson EM, Keegan AD. Interleukin-13 (IL-13) pathway. Sci STKE, 2005 Jul 19, 2005(293):cm8
[42] Fertin C, Nicolas JF, Gillery P, et al. Interleukin-4 stimulates collagen synthesis by normal and scleroderma fibroblasts in dermal equivalents. Cell Mol Biol, 1991, Vol. 37(8): 823-829
[43] Zurawski SM, Vega F Jr, Huyghe B, et al. Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J, 1993, Vol. 12(7): 2663-2670
[44] Saito A, Okazaki H, Sugawara I, et al. Potential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro. Int Arch. Allergy Immunol, 2003, Vol. 132(2): 168-176
[45] Webb DC, McKenzie AN, Koskinen AM, et al. Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. J Immunol, 2000, Vol. 165(1): 108-113
[46] Walter DM, McIntire JJ, Berry G, et al. Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J Immunol, 2001, Vol. 167(8): 4668-4675
[47] Fallon PG, Richardson EJ, McKenzie GJ, et al. Schistosome infection of transgenic micedefines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. J Immunol, 2000, Vol. 164(5): 2585-2591
[48] Kumar RK, Herbert C, Yang M, et al. Role of interleukin-13 in eosinophil accumulation and airway remodelling in a mouse model of chronic asthma. Clin Exp Allergy, 2002, Vol. 32(7): 1104-1111
[49] Oriente A, Fedarko NS, Pacocha SE, et al. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther, 2000, Vol. 292(3):988-994
[50] Lanone S, Zheng T, Zhu Z, et al. Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and –12 in IL-13-induced inflammation and remodeling. J Clin Invest, 2002, Vol. 110(4): 463-474
[51] Kaviratne M, Hesse M, Leusink M, et al. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol, 2004, Vol. 173(6):4020-4029
[52] Obiri NI, Debinski W, Leonard WJ, et al. Receptor for interleukin 13 interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem, 1995, Vol. 270(15):8797-8804
[53] Mentink-Kane MM, Wynn TA. Opposing roles for IL-13 and IL-13 receptor alpha 2 in health and disease. Immunol Rev, 2004, Vol. 202: 191-202
[54] Arima K, Sato K, Tanaka G, et al. Characterization of the interaction between interleukin-13 and interleukin-13 receptors. J Biol Chem, 2005, Vol. 280(26):24915-24922
[55] Murata T, Husain SR, Mohri H, et al. Two different IL-13 receptor chains are expressed in normal human skin fibroblasts, and IL-4 and IL-13 mediate signal transduction through a common pathway. Int Immunol, 1998, Vol. 10(8):1103-1110
[56] Kelly-Welch AE , Hanson EM ,et al. Interleukin-4 and interleukin-13 signaling connections maps. Science, 2003, Vol. 300(6):1527-1528
[57] Hershey GK. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol. 2003, Vol. 111(4):677-690
[58] Ingram GL, Antao-Menezes A, Mangum JB, et al. Opposing actions of Stat1 and Stat6 on IL-13-induced up-regulation of early growth response-1 and platelet-derived growth factor ligands in pulmonary fibroblasts. J Immunol, 2006, Vol. 177(6):4141-4148
[59] Palmqvist P, Lundberg P, Persson E, et al. Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway. J Biol Chem, 2006, Vol. 281(5): 2414-2429
[60] Cordula B, Annett S, Ernst P R.. Transcriptional activation of the type I collagen genes COL1A1 and COL1A2 in fibroblasts by interleukin-4: analysis of the functional collagen promoter sequences. J Cell Physiol, 2004, Vol. 198(2): 248-258
[61] Tracy L M, Maithao L, Takao K, et al. Molecular mechanisms of interleukin-4-induced up-regulation of type I collagen gene expression in murine fibroblasts. Arthritis Rheumatis, 2003, Vol. 48(8): 2275-2284
[62] Granstein RD, Flotte TJ, Amento EP. Interferons and collagen production. J Invest Dermatol, 1990, Vol. 95(6 Suppl): 75S-80S
[63] Cen Y, Yan XR. Effect of gamma-interferon on the fibroblasts in hypertrophic scars. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, 1999, Vol. 13(2): 122-126
[64] Kim WJ. Cellular signaling in tissue regeneration. Yonsei Med J, 2000, Vol. 41(6): 692-703
[65] Joshi BH, Hogaboam C, Dover P, et al. Role of interleukin-13 in cancer, pulmonary fibrosis, and other T(H)2-type diseases. Vitam Horm 2006, Vol. 74: 479-504
[66] 高春芳. 胶原基因转录调控与纤维化. 世界华人消化杂志, 2005, 13(2): 166-171
[67] Wu J, Reinhardt DP, Batmunkh C, et al. Functional diversity of lysyl hydroxylase 2 in collagen synthesis of human dermal fibroblasts. Exp Cell Res, 2006, Vol. 312 (18): 3485-3494
[68] Gharaee-Kermani M, Phan SH. Molecular mechanisms of and possible treatment strategies for idiopathic pulmonary fibrosis. Curr Pharm Des, 2005, Vol. 11(30):3943-3971
[69] Bataller R, Brenner DA. Liver fibrosis. J Clin Invest, 2005, Vol. 115(2):209-218
[70] 司徒镇强, 吴军正主编. 细胞培养第一版. 北京:世界图书出版社, 2001. 43-57
[71] 鄂征等主编. 组织培养和分子细胞学技术. 北京:北京出版社, 1995. 120-138
[72] 萨姆布鲁克 J,弗里奇 E.F,曼尼阿蒂斯 T 主编. 分子克隆实验指南第三版. 北京:科学出版社, 2003. 385-455; 1681-1727
[73] 奥斯伯 F,布伦特 R,金斯顿 R E 主编. 精编分子生物学实验指南. 北京:科学出版社, 2003. 329-373
[74] 汪家政,范明主编. 蛋白质技术手册. 上海:科学出版社, 2001. 166-184
[75] Kaufman J, Sime PJ, Phipps RP. Expression of CD154 (CD40 ligand) by human lung fibroblasts: differential regulation by IFN-γ and IL-13, and implications for fibrosis. J Immunol, 2004, Vol. 172(3): 1862-1871
[76] Tsukada S, Westwick JK, Ikejima K, et al. SMAD and p38 MAPK signaling pathways independently regulate alpha1(I) collagen gene expression in unstimulated and transforming growth factor-beta-stimulated hepatic stellate cells. J Biol Chem, 2005, Vol. 280(11):10055-10064
[77] Higashi K, Inagaki Y, Fujimori K, et al. Interferon-gamma interferes with transforming growth factor-beta signaling through direct interaction of YB-1 with Smad3. J Biol Chem, 2003, Vol. 278(44):43470-43479
[78] Ramirez F, Tanaka S, Bou-Gharios G. Transcriptional regulation of the human alpha2(I) collagen gene (COL1A2), an informative model system to study fibrotic diseases. Matrix Biol, 2006, Vol. 25(6):365-372
[79] Gao CF, Wang H, Wang AH, et al. Transcriptional regulation of human alpha1(I) procollagen gene in dermal fibroblasts. World J Gastroenterol, 2004, Vol. 10(10): 1447-1451
[80] Lindahl GE, Chambers RC, Papakrivopoulou J, et al. Activation of fibroblast procollagen alpha 1(I) transcription by mechanical strain is transforming growth factor-beta-dependent and involves increased binding of CCAAT-binding factor (CBF/NF-Y) at the proximalpromoter. J Biol Chem, 2002, Vol. 277(8):6153-6161
[81] Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest, 1999, Vol. 103(6):779-788
[82] Chiaramonte MG, Donaldson DD, Cheever AW, et al. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest, 1999, Vol. 104(6):777-785
[83] Kolodsick JE, Toews GB, Jakubzick C,et al. Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts. J Immunol, 2004, Vol. 172(7):4068-4076
[84] Jinnin M, Ihn H, Asano Y, et al. Upregulation of tenascin-C expression by IL-13 in human dermal fibroblasts via the phosphoinositide 3-kinase/Akt and the protein kinase C signaling pathways. J Invest Dermatol, 2006, Vol. 126(3):551-560
[85] Jinnin M, Ihn H, Yamane K, et al. Interleukin- 13 stimulates the transcription of the human alpha2(I) collagen gene in human dermal fibroblasts. J Biol Chem, 2004, Vol. 279(40):41783-91
[86] Zhou X, Hu H, Huynh ML, et al. Mechanisms of tissue inhibitor of metalloproteinase 1 augmentation by IL-13 on TGF-beta1-stimulated primary human fibroblasts. J Allergy Clin Immunol, 2007 Apr 4; [Epub ahead of print]
[87] Fichtner-Feigl S, Strober W, Kawakami K, et al. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med, 2006, Vol. 12(1): 99-106
[88] Benekli MB, Baer MR, Baumann H, et al. Signal transducer and activator of transcription proteins in leukemias. Blood, 2003, Vol. 101(8): 2940-2950
[89] 杨洁,姚智等. 人p100蛋白:可增强STAT6基因转录活性的新因子. 中国免疫学杂志, 2004, 20(11):739-742
[90] Calo V , Migliavacca M, Bazan V,et al. STAT proteins: from normal control of cellular events to tumorigenesis. J Cellular Physiol, 2003, Vol. 197(2):157–168
[91] Daines MO, Andrews RP, Chen WG, et al. DNA binding activity of cytoplasmic phosphorylated Stat6 is masked by an interaction with a detergent-sensitive factor. J Biol Chem, 2003, Vol. 278(33): 30971-30974
[92] 叶乐平.信号转导子和转录激活子 6 与支气管哮喘.国外医学儿科学分册, 2003, 9(5):234-236.
[93] Chen W, Daines Mo, Hershey GK. Methylation of STAT6 modulates STAT6 phosphorylation, nuclear translocation, and DNA-binding activity. J Immunol, 2004, Vol. 172(11):6744-6750
[94] Malefyt RDW, Figdor CG, Huijbens R, et al. Effects of IL-13 on phenotype,cytokine production, and cytotoxic function of human monocytes. J Immunol, 1993, Vol. 151: 6370-6381
[95] Yoshikawa M, Nakajima T, Tsukidate T, et al. TNF-alpha and IL-4 regulate expression of IL-13 receptor alpha2 on human fibroblasts. Biochem Biophys Res Commun, 2003, Vol. 312(4):1248-55
[96] Kato A, Kawamata N, Tamayose K, et al. Ancient ubiquitious protein 1 binds to the conserved membrane-proximal sequence of the cytoplasmic tail of the integrin α subunits that plays a crucial role in the inside-out signaling of αIIbβ3. J Biol Chem, 2002, Vol. 277(32): 28934-28941
[97] Orchansky PL, Kwan R, Lee F, et al. Characterization of the cytoplasmic domain of Interleukin-13 receptor-α. J Bio Chem, 1999, Vol. 274(30):20818-20825
[98] Zhang JG, Hilton DJ , et al. Identification, purification, and characterization of a soluble interleukin(IL)-13-binding protein. J Biol Chem, 1997, Vol. 272(14):9474- 9480
[99] Murata T, Obiri NI, Debinski W, et al. Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem Biophys Res Commun, 1997, Vol. 238(1):90-94
[100] David M, Ford D, Bertoglio J, et al. Induction of the IL-13 receptor α2-chain by IL-4 and IL-13 in human keratinocytes: involvement of STAT6, ERk and p38 MAPK pathways. Oncogene, 2001, Vol. 20 (46):6660-6668
[101] Donnelly LE, Barnes PJ,et al. Acidic mammalian chitinase--a potential target for asthma therapy. Trends Pharmacol Sci, 2004, Vol. 25(10):509-511
[102]Guiter C, Dusanter-Fourt I, Copie-Bergman C,et al. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood, 2004, Vol. 104(2):543-549
[103]Finkelman FD, Shea-Donohue T, Morris SC. Interleukin-4 and interleukin-13-mediated host protection against intestinal nematode parasites. Immunol Rev, 2004, Vol. 201:139-55
[104]Liu T, Jin H, Ullenbruch M, et al. Regulation of found in inflammatory zone 1 expression in bleomycin-induced lung fibrosis: role of IL-4/IL-13 and mediation via STAT-6. J Immunol, 2004, Vol. 173(5):3425-3431
[105]Hoeck J, woisetschlager M. Activation of eotaxin-3/CCLl26 gene expression in human dermal fibroblasts is mediated by STAT6.J Immunol, 2001, Vol. 167(6):3216-3222
[106]Hebenstreit D, Wirnsberger G, Horejs-Hoech J, et al. Signaling mechanisms, interaction partners, and target genes of STAT6. Cytokine Growth Factor Rev, 2006, Vol.17(3):173-88
[107]Andrews RP, Ericksen MB, Cunningham CM, et al. Analysis of the life cycle of Stat6. J Biol Chem, 2002, Vol. 277(39):36563-36569
[108]Losman JA, Chen XP, Hilton D, et al. Cutting Edge: SOCS-1 is a potent inhibitor of IL-4 signal transduction. J Immunol, 1999, Vol. 162(7): 3770-3774
[109]Hanson EM,Dickensheets H,QU CK, et al. Regulation of the dephosphorylation of Stat6. J Biol Chem, 2003, Vol. 278(6):3903-3911
[110]Andrews AL, Holloway JW, Puddicombe SM. Kinetic analysis of the interleukin-13 receptor complex. J Biol Chem, 2002, Vol. 277(48): 46073-46078
[111]Shuai K. Modulation of STAT signaling by STAT-interacting proteins. Oncogene, 2000, Vol.19(21): 2638-2644
[112]V?lineva T, Yang J, Palovuori R, et al. The transcriptional co-activator protein p100 recruits histone acetyltransferase activity to STAT6 and mediates interaction between the CREB-binding protein and STAT6. J Biol Chem, 2005, Vol. 280(15): 14989–14996
[113]Popescu FD. New asthma drugs acting on gene expression. J Cell Mol Med, 2003, Vol. 7(4):475-486
[114]Bennett BL, Cruz R, lacson RG, et al. Interleukin-4 suppression of tumor necrosis factor -stimulated E-selectin gene transcription is mediated by STAT6 antagonism of NF- B. J Biol Chem, 1997, Vol. 272(15):10212-10219
[115]Wurster AL, Rodgers VL, White MF, et al. Interleukin-4-mediated protection of primary B cells from apoptosis through Stat6-dependent up-regulation of Bcl-xL. J Biol Chem, 2002, Vol. 277(30):27169-27175
[116]Bhogal RK, Stoica CM, McGaha TL, et al. Molecular aspects of regulation of collagen gene expression in fibrosis. J Clin Immunol, 2005, Vol. 25(6): 592-603
[117]Cobb MH.MAP kinase pathways.Prog Biophys Mol Biol.1999, Vol. 71(3-4): 479-500
[118]Ruckemann K, Fairbanks LD, Carrey EA, et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem, 1998, Vol. 273 (34): 21682-21691.
[119]Mattar T, Kochhar K, Bartlett R, et al. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett, 1993, Vol. 334(2):161-164
[120]Klausner RD, Samelson LE. T cell antigen receptor activation pathway; the tyrosine kinase connection. Cell, 1991, Vol. 64(5):875-878
[121]Tomita N, Morishita R, Lan HY, et al. In vivo administration of a nuclear transcription factor-kappaB decoy suppresses experimental crescentic glomerulonephritis. J Am Soc Nephrol, 2000, Vol. 11(7):124-129
[122]Siemasko K, Chong A S, Jack HM , et al. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immuno suppressive drug leflunomide leads to block in IgG1 production. J Immunol,1998, 160 (4) : 1581-1588
[123]Fox RI, Herrmann ML, Frangou CG, et al. Mechanism of action for leflunomide in arthritis. Clin Immunol, 1999, Vol. 93 (3): 198-208
[124]Xu X, Williams JW, Gong H, et al. Two activities of the immunosuppressive metabolite of leflunomide, A77 1726 Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Biochem Pharmacol, 1996, Vol. 52(4):527-534
[125]SIEMASKO K,CHONG AS , JACK HM , et al . Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosup2 pressive drug leflunomide leads to a block in IgG1 production. J Immuonol, 1998, Vol. 160 (4) : 1581-1588
[126]Jarman ER, Kuba A, Montermann E, et al. Inhibition of murine IgE and immediate cutaneous hypersensitivity responses to ovalbumin by the immunomodulatory agent leflunomide. Clin Exp Immunol, 1999, Vol. 115 (2): 2212-2228
[127]Kraan MC, Reece RJ, Barg EC, et al. Modulation of inflammation and metallopteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Arthritis Rheum, 2000, Vol. 42 (8): 1820-1830
[128]Si HF, Li J, Lu XW, et al. Suppressive effects of leflunomide on leptin-induced collagen I involved in hepatic stellate cell proliferation. Exp Biol Med (Maywood), 2007, Vol. 232(3): 427-436
[129]Yao HW, Li J, Chen JQ, et al. Inhibitory effect of leflunomide on hepatic fibrosis induced by CCl4 in rats. Acta Pharmacol Sin, 2004, Vol. 25(7): 915-920
[130]姚宏伟,李俊,陈季强,等.来氟米特对肝星状细胞增殖和胶原合成的影响.浙江大学学报(医学版), 2004, 33(6): 515-518
[131]Akiho H, Lovato P, Deng Y, et al. Interleukin-4- and -13-induced hypercontractility of human intestinal muscle cells-implication for motility changes in Crohn's disease. Am J Physiol Gastrointest Liver Physiol, 2005, Vol. 288(4): G609- G615
[132]Kagami S,Saeki H.Interleukin-4 and interleukin-13 enhance CCL26 production in a human keratinocyte cell line, HaCaT cells. Inflamm Res, 2006, Vol. 55(11):469-475.
[133]Latchoumycandane C, Seah QM, Leflunomide or A77 1726 protect from -induced cell injury through inhibition of JNK-mediated mitochondrial permeability transition in immortalized human hepatocytes. Glycobiology, 1996, Vol. 6(4):399-406
[134]Tredget EE, Yang L, Delehanty M, et al. Polarized Th2 cytokine production in patients with hypertrophic scar following thermal injury. J Interferon Cytokine Res, 2006, Vol. 26(3): 179-189
[135]Tredget EE, Wang R, Shen Q, et al. Transforming growth factor-beta mRNA and protein in hypertrophic scar tissues and fibroblasts: antagonism by IFN-alpha and IFN-gamma in vitro and in vivo. J Interferon Cytokine Res, 2000, Vol. 20(2): 143-151
[136]Aliprantis AO, Wang J, Fathman JW, et al. Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci U S A. 2007, Vol. 104(8): 2827-2830.
[137]Lakos G, Melichian D, Wu M, et al. Increased bleomycin-induced skin fibrosis in mice lacking the Th1-specific transcription factor T-bet. Pathobiology, 2006, Vol. 73(5): 224-237
[138]Grassegger A, Hopfl R. Significance of the cytokine interferon gamma in clinical dermatology. Clin Exp Dermatol, 2004, Vol. 29(6): 584-588
[139]Pittet B, Rubbia-Brandt L, Desmouliere A, et a1. Effect of gamma-interferon on the clinical and biologic evolution of hypertrophic scars and Dupuytren's disease: an open pilot study. P1ast Reconstr Surg, 1994, Vol. 93(6): 1224-1235
[1] Wynn TA. Fibrotic disease and the TH1/ TH2 paradigm. Nature Rev Immunol,2004, Vol. 4(8): 583–594
[2] Wynn TA, Cheever AW, Jankovic D, et al. An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature, 1995, Vol. 376(6541): 594–596
[3] Hoffmann KF, Cheever AW, Wynn TA. IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis. J Immunol, 2000, Vol. 164(12): 6406–6416
[4] Gurujeyalakshmi G, Giri SN. Molecular mechanisms of antifibrotic effect of interferon-γ i?n bleomycin-mouse model of lung fibrosis: downregulation of TGF-β a?nd procollagen I and III gene expression. Exp Lung Res, 1995, Vol. 21(5): 791–808
[5] Keane MP, Belperio JA, Burdick MD, et al. IL-12 attenuates bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol, 2001, Vol. 281(1): L92–L97
[6] Oldroyd SD, Thomas GL, Gabbiani G, et al. Interferon-gamma i?nhibits experimental renal fibrosis. Kidney Int, 1999, Vol. 56(6): 2116–2127
[7] Poynard T, Yuen MF, Ratziu V, et al. Viral hepatitis C. Lancet, 2003, Vol. 362(9401): 2095–2100
[8] Hesse M, Cheever AW, Jankovic D, et al. NOS-2 mediates the protective anti-inflammatory and antifibrotic effects of the TH1-inducing adjuvant, IL-12, in a TH2 model of granulomatous disease. Am J Pathol, 2000, Vol. 157(3): 945–955
[9] Hoffmann KF, McLarty TC, Seqal DH, et al. Disease fingerprinting with cDNA microarrays reveals distinct gene expression profiles in lethal type 1 and type 2 cytokine-mediated inflammatory reactions. FASEB J, 2001, Vol. 15(13): 2545–2547
[10] Sandler NG, Mentink-Kane MM, Cheever AW, et al. Global gene expression profiles during acute pathogen-induced pulmonary inflammation reveal divergent roles for TH1 and TH2 responses in tissue repair. J Immunol, 2003, Vol. 171(7): 3655–3667
[11] Walker LS, Abbas AK. The enemy within: keeping self-reactive T cells at bay in the periphery. Nature Rev Immunol, 2002, Vol. 2(1): 11–19
[12] Hesse M, Modolell M, La Flamme AC, et al. Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism. J Immunol, 2001, Vol. 167(11): 6533–6544
[13] Decitre M, Gleyzal C, Raccurt M, et al. Lysyl oxidase-like protein localizes to sites of de novo fibrinogenesis in fibrosis and in the early stromal reaction of ductal breast carcinomas. Lab Invest, 1998, Vol. 78(2): 143–151
[14] Wang S, Hirschberg R. BMP7 antagonizes TGF-β-dependent fibrogenesis in mesangial cells. Am J Physiol Renal Physiol. 2003, Vol. 284(5): F1006–F1013
[15] Underwood DC, Osborn RR, Bochnowicz S, et al. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol. 2000, Vol. 279(5): L895–L902
[16] Kim H, Oda T, Lopez-Guisa J, et al. TIMP-1 deficiency does not attenuate interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol, 2001, Vol. 12(4): 736–748
[17] Vaillant B, Chiaramonte M, Cheever AW, et al. Regulation of hepatic fibrosis and extracellular matrix genes by the TH response: new insight into the role of tissue inhibitors of matrix metalloproteinases. J Immunol, 2001, Vol. 167(12): 7017–7026
[18] Kaminski N, Allard JD, Pittet JF, et al. Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis. Proc Natl Acad Sci USA , 2000, Vol. 97(4): 1778–1783
[19] Kristensen DB, Kawada N, Imamura K, et al. Proteome analysis of rat hepatic stellate cells. Hepatology, 2000, Vol. 32(2): 268–277
[20] Emura M, Naqai S, TaKeuchi M, et al. In vitro production of B cell growth factor and B cell differentiation factor by peripheral blood mononuclear cells and bronchoalveolar lavage T lymphocytes from patients with idiopathic pulmonary fibrosis. Clin Exp Immunol, 1990, Vol. 82(1): 133–139
[21] Wallace WA, Ramage EA, Lamb D, et al. A type 2 (TH2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA). Clin Exp Immunol, 1995, Vol. 101(3): 436–441
[22] Booth M, Mwatha JK, Joseph S, et al. Periportal fibrosis in human Schistosoma mansoni infection is associated with low IL-10, low IFN-γ, high TNF-α, or low RANTES, depending on age and gender. J. Immunol, 2004, Vol. 172(2): 1295–1303
[23] Buttner C, Skupin A, Reimann T, et al. Local production of interleukin-4 during radiation-induced pneumonitis and pulmonary fibrosis in rats: macrophages as a prominent source of interleukin-4. Am J Respir Cell Mol Biol, 1997, Vol. 17(3): 315–325
[24] Fertin C, Nicolas JF, Gillery P, et al. Interleukin-4 stimulates collagen synthesis by normal and scleroderma fibroblasts in dermal equivalents. Cell Mol Biol, 1991, Vol. 37(8): 823–829
[25] Letterio JJ, Roberts AB. Regulation of immune responses by TGF-β. Annu Rev Immunol,1998, Vol. 16: 137–161
[26] Sempowski GD, Beckmann MP, Derdak S, et al. Subsets of murine lung fibroblasts express membrane-bound and soluble IL-4 receptors. Role of IL-4 in enhancing fibroblast proliferation and collagen synthesis. J Immunol, 1994, Vol. 152(7): 3606–3614
[27] Doucet C, Brouty-Boye D, Pottin-ClemenceauC, et al. Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. J Clin Invest , 1998, Vol. 101(10): 2129–2139
[28] Tiggelman AM, Boers W, Linthorst C, et al. Collagen synthesis by human liver (myo)fibroblasts in culture: evidence for a regulatory role of IL-1β, IL-4, TGF-β and IFN-γ. J Hepatol, 1995, Vol. 23(3): 307–317
[29] Cheever AW, Williams ME, Wynn TA, et al. Anti-IL-4 treatment of Schistosoma mansoni-infected mice inhibits development of T cells and non-B, non-T cells expressing TH2 cytokines while decreasing egg-induced hepatic fibrosis. J Immunol, 1994, Vol. 153(2): 753–759
[30] Ong C, Wong C, Roberts CR, et al. Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol, 1998, Vol. 28(9): 2619–2629
[31] Le MA, Flamand V, Demoor FX, et al. Critical roles for IL-4, IL-5, and eosinophils in chronic skin allograft rejection. J Clin Invest, 1999, Vol. 103(12): 1659–1667
[32] Zurawski SM, Vega F Jr, Huyghe B, et al. Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J, 1993, Vol. 12(7): 2663–2670
[33] McKenzie GJ, Emson CL, Bell SE, et al. Impaired development of TH2 cells in IL-13-deficient mice. Immunity, 1998, Vol. 9(3): 423–432
[34] Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest, 1999, Vol. 103(6): 779–788
[35] Donaldson DD, Whitters MJ, Fitz LJ, et al. The murine IL-13 receptor α2: molecular cloning, characterization, and comparison with murine IL-13 receptor α1. J Immunol, 1998, Vol. 161(5): 2317–2324
[36] Chiaramonte MG, Donaldson DD, Cheever AW, et al. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest, 1999, Vol. 104(6): 777–785
[37] Blease K, Jakubzick C, Westwick J, et al. Therapeutic effect of IL-13 immunoneutralization during chronic experimental fungal asthma. J Immunol, 2001, Vol. 166(8): 5219–5224
[38] Kumar RK, Herbert C, Yang M, et al. Role of interleukin-13 in eosinophil accumulation and airway remodelling in a mouse model of chronic asthma. Clin Exp Allergy, 2002, Vol. 32(7): 1104–1111
[39] Chiaramonte MG, Cheever AW, Malley JD, et al. Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis. Hepatology, 2001, Vol. 34(2): 273–282
[40] Fallon PG, Richardson EJ, McKenzie GJ, et al. Schistosome infection of transgenic micedefines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. J Immunol, 2000, Vol. 164(5): 2585–2591
[41] Belperio JA, Dy M, Burdick MD, et al. Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol, 2002, Vol. 27(4): 419–427
[42] Rankin JA, Picarella DE, Geba GP, et al. Phenotypic and physiologic characterization of transgenic mice expressing interleukin 4 in the lung: lymphocytic and eosinophilic inflammation without airway hyperreactivity. Proc Natl Acad Sci USA, 1996, Vol. 93(15): 7821–7825
[43] Murata T, Husain SR, Mohri H, et al. Two different IL-13 receptor chains are expressed in normal human skin fibroblasts, and IL-4 and IL-13 mediate signal transduction through a common pathway. Int Immunol, 1998, Vol. 10(8): 1103–1110
[44] Oriente A, Fedarko NS, Pacocha SE, et al. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther, 2000, Vol. 292(3): 988–994
[45] Saito A, Okazaki H, Sugawara I, et al. Potential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro. Int Arch Allergy Immunol, 2003, Vol. 132(2): 168–176
[46] Blease K, Schuh JM, Jakubzick C, et al. Stat6-deficient mice develop airway hyperresponsiveness and peribronchial fibrosis during chronic fungal asthma. Am J Pathol, 2002, Vol. 160(2): 481–490
[47] Webb DC, McKenzie AN, Koskinen AM, et al. Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. J Immunol, 2000, Vol. 165(1): 108–113
[48] Walter DM, McIntire JJ, Berry G, et al. Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J Immunol, 2001, Vol. 167(8): 4668–4675
[49] Webb DC, Mahalinqam S, Cai Y, et al. Antigen-specific production of interleukin (IL)-13 and IL-5 cooperate to mediate IL-4Rα-independent airway hyperreactivity. Eur J Immunol, 2003, Vol. 33(12): 3377–3385
[50] Gharaee-Kermani M, Phan SH. Lung interleukin-5 expression in murine bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol, 1997, Vol. 16(4): 438–447
[51] Sher A, Coffman RL, Heiny S, et al. Interleukin 5 is required for the blood and tissue eosinophilia but not granuloma formation induced by infection with Schistosoma mansoni. Proc Natl Acad Sci USA, 1990, Vol. 87(1): 61–64
[52] Hao H, Cohen DA, Jennings CD, et al. Bleomycin-induced pulmonary fibrosis is independent of eosinophils. J Leukoc Biol, 2000, Vol. 68(4): 515–521
[53] Gharaee-Kermani M, McGatty B, Lukaca N, et al. The role of IL-5 in bleomycininduced pulmonary fibrosis. J Leukoc Biol, 1998, Vol. 64(5): 657–666
[54] Blyth DI, Wharton TF, Pedrick MS, et al. Airway subepithelial fibrosis in a murine model of atopic asthma: suppression by dexamethasone or antiinterleukin-5 antibody. Am J Respir Cell Mol Biol, 2000, Vol. 23(2): 241–246
[55] Cho JY, Miller M, Baek KJ, et al. Inhibition of airway remodeling in IL-5-deficient mice. J Clin Invest, 2004, Vol. 113(4): 551–560
[56] Huaux F, Liu T, McGarry B, et al. Eosinophils and T lymphocytes possess distinct roles inbleomycin-induced lung injury and fibrosis. J Immunol, 2003, Vol. 171(10): 5470–5481
[57] Mattes J, Yang M, Mahalingam S, et al. Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma. J Exp Med, 2002, Vol. 195(11): 1433–1444
[58] Sato M, Muragaki Y, Saika S, et al. Targeted disruption of TGF-β1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest, 2003, Vol. 112(10): 1486–1494
[59] Border WA, Noble NA, Yamamoto T, et al. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature, 1992, Vol. 360 (6402): 361–364
[60] Clouthier DE, Comerford SA, Hammer RE. Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK–TGF-β1 transgenic mice. J Clin Invest, 1997, Vol. 100(11): 2697–2713
[61] Sime PJ, Xing Z, Graham FL, et al. Adenovector-mediated gene transfer of active transforming growth factor-β1 induces prolonged severe fibrosis in rat lung. J Clin Invest, 1997, Vol. 100(4): 768–776
[62] Gorelik L, Flavell RA. Transforming growth factor-β in T-cell biology. Nature Rev Immunol, 2002, Vol. 2(1): 46–53
[63] Munger JS, Huang X, Kawakatsu H, et al. The integrin-αvβ6 binds and activates latent TGF-β1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell, 1999, Vol. 96(3): 319–328
[64] Roberts AB, Russo A, Felici A, et al. Smad3: a key player in pathogenetic mechanisms dependent on TGF-β. Ann NY Acad Sci, 2003, Vol. 995 (1): 1–10
[65] Flanders KC, Sullivan CD, Fujii M, et al. Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am J Pathol, 2002, Vol. 160(3): 1057–1068
[66] Khalil N, Corne S, Whitman C, et al. Plasmin regulates the activation of cell-associated latent TGF-β1 secreted by rat alveolar macrophages after in vivo bleomycin injury. Am J Respir Cell Mol Biol, 1996, Vol. 15(2): 252–259
[67] Ma LJ, Yang H, Gaspert A, et al. Transforming growth factor-β-dependent and -independent pathways of induction of tubulointerstitial fibrosis in β6–/– mice. Am J Pathol, 2003, Vol. 163(4): 1261–1273
[68] Ashcroft GS, Yang H, Glick AB, et al. Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nature Cell Biol, 1999, Vol. 1(5): 260–266
[69] Kaviratne M, Hesse M, Leusink M, et al. IL-13 activates a mechanism of liver fibrosis that is completely TGF-β independent. J Immunol, 2004, Vol. 173(6): 4020-4029
[70] Lee CG, Homer RJ, Zhu Z, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor β1. J Exp Med, 2001, Vol. 194(6): 809–821
[71] Lanone S, Zheng T, Zhu Z, et al. Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and –12 in IL-13-induced inflammation and remodeling. J Clin Invest, 2002,Vol. 110(4): 463–474
[72] Nakao A, Miike S, Hatano M, et al. Blockade of transforming growth factor-β/Smad signaling in T cells by overexpression of Smad7 enhances antigen-induced airway inflammation and airway reactivity. J Exp Med, 2000, Vol. 192(2): 151–158
[73] Hansen G, McIntire JJ, Yeung VP, et al. CD4+ T helper cells engineered to produce latent TGF-β1 reverse allergen-induced airway hyperreactivity and inflammation. J Clin Invest, 2000, Vol. 105(1): 61–70
[74] Kitani A, Fuss I, Naka mura K, et al. Transforming growth factor (TGF)- β1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-β1- mediated fibrosis. J Exp Med, 2003, Vol. 198(8): 1179–1188
[75] Kulkarni AB, Huh CG, Bexker D, et al. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA, 1993, Vol. 90(2): 770–774
[76] Smith RE, Strieter RM, Phan SH, et al. Production and function of murine macrophage inflammatory protein-1α in bleomycin-induced lung injury. J Immunol, 1994, Vol. 153(10): 4704–4712
[77] Smith RE, Strieter RM, Zhang K, et al. A role for CC chemokines in fibrotic lung disease. J Leukoc Biol, 1995, Vol. 57(5): 782–787
[78] Lloyd CM, Minto AW, Dorf ME, et al. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med, 1997, Vol. 185(7): 1371–1380
[79] Belperio JA, Keane MP, Burdick MD, et al. Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J Clin Invest, 2001, Vol. 108(4): 547–556
[80] Tokuda A, Itakura M, Onai N, et al. Pivotal role of CCR1-positive leukocytes in bleomycin-induced lung fibrosis in mice. J Immunol, 2000, Vol. 164(5): 2745–2751
[81] Blease K, Mehrad B, Standiford TJ, et al. Airway remodeling is absent in CCR1–/– mice during chronic fungal allergic airway disease. J Immunol, 2000, Vol. 165(3): 1564–1572
[82] Anders HJ, Vielhauer V, Frink M, et al. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Invest, 2002, Vol. 109(2): 251–259
[83] Moore BB, Paine R 3rd, Christensen PJ, et al. Protection from pulmonary fibrosis in the absence of CCR2 signaling. J Immunol, 2001, Vol. 167(8): 4368–4377
[84] Zhu Z, Ma B, Zheng T, et al. IL-13-induced chemokine responses in the lung: role of CCR2 in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol, 2002, Vol. 168(6): 2953–2962
[85] Gao JL, Wynn TA, Chang Y, et al. Impaired host defense, hematopoiesis, granulomatous inflammation and type 1/type 2 cytokine balance in mice lacking CC chemokine receptor 1. J Exp Med, 1997, Vol. 185(11): 1959–1968
[86] Ma B, Zhu Z, Homer RJ, et al. The C10/CCL6 chemokine and CCR1 play critical roles in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol, 2004, Vol. 172(3): 1872–1881
[87] Gordon S. Alternative activation of macrophages[J]. Nature Rev Immunol, 2003, 3(1): 23–35.
[88] Munder M, Eichmann K, Modolell M. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with TH1/TH2 phenotype. J Immunol, 1998, Vol. 160(11): 5347–5354
[89] Munder M, Eichmann K, Moran JM, et al. TH1/TH2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol, 1999, Vol. 163(7): 3771–3777
[90] Witte MB, Barbul A, Schick MA, et al. Upregulation of arginase expression in wound-derived fibroblasts. J Surg Res, 2002, Vol. 105(1): 35–42
[91] Zimmermann N, King NE, Laporte J, et al. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J Clin Invest, 2003, Vol. 111(12): 1863–1874
[92] Hogaboam CM, Gallinat CS, Bone-Larson C, et al. Collagen deposition in a non-fibrotic lung granuloma model after nitric oxide inhibition. Am J Pathol, 1998, Vol. 153(6): 1861–1872
[93] Numaguchi K, Eqashira K, Takemoto M, et al. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension, 1995, Vol. 26(6 Pt 1): 957–962
[94] Moore KW, de Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol, 2001, Vol. 19: 683–765
[95] Thompson K, Maltby J, Fallowfield J, et al. Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis. Hepatology, 1998, Vol. 28(6): 1597–1606
[96] Louis H, Van Laethem JL, Wu W, et al. Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice. Hepatology, 1998, Vol. 28(6): 1607–1615
[97] Arai T, Abe K, Matsuoka H, et al. Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo. Am J Physiol Lung Cell Mol Physiol, 2000, Vol. 278(5): L914–L922
[98] Demols A, Van Laethem JL, Quertinmont E, et al. Endogenous interleukin-10 modulates fibrosis and regeneration in experimental chronic pancreatitis. Am J Physiol Gastrointest Liver Physiol, 2002, Vol. 282(6): G1105–G1112
[99] Wangoo A, Laban C, Cook HT, et al. Interleukin-10- and corticosteroid-induced reduction in type I procollagen in a human ex vivo scar culture. Int J Exp Pathol, 1997, Vol. 78(1): 33–41
[100] Wang SC, Ohata M, Schrum L, et al. Expression of interleukin-10 by in vitro and in vivo activated hepatic stellate cells. J Biol Chem, 1998, Vol. 273(1): 302–308
[101] Nelson DR, Tu Z, Soldevila-Pico C, et al. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology, 2003, Vol. 38(4): 859–868
[102] Wynn TA, Cheever AW, Williams ME, et al. IL-10 regulates liver pathology in acute murine Schistosomiasis mansoni but is not required for immune down-modulation of chronic disease. J Immunol, 1998, Vol. 160(9): 4473–4480
[103] Hesse M, Piccirillo CA, Belkaid Y, et al. The pathogenesis of schistosomiasis is controlled by cooperating IL-10-producing innate effector and regulatory T cells. J Immunol, 2004, Vol. 172(5): 3157–3166
[104] Lee CG, Homer RJ, Cohn L, et al. Transgenic overexpression of interleukin (IL)-10 in the lung causes mucus metaplasia, tissue inflammation, and airway remodeling via IL-13-dependent and -independent pathways. J Biol Chem, 2002, Vol. 277(38): 35466–35474
[105] Taube C, Duez C, Cui ZH, et al. The role of IL-13 in established allergic airway disease. J Immunol, 2002, Vol. 169(11): 6482–6489
[106] Mattes J, Yang M, Siqueira A, et al. IL-13 induces airways hyperreactivity independently of the IL-4R α-chain in the allergic lung. J Immunol, 2001, Vol. 167(3): 1683–1692
[107] Feng N, Luqli SM, Schnyder B, et al. The interleukin-4/interleukin-13 receptor of human synovial fibroblasts: overexpression of the nonsignaling interleukin-13 receptor α2. Lab Invest, 1998, Vol. 78(5): 591–602
[108] Wood N, Whitters MJ, Jacobson BA, et al. Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor α2. J Exp Med, 2003, Vol. 197(6): 703–709
[109] Chiaramonte MG, Mentink-Kane M, Jacobson BA, et al. Regulation and function of the interleukin 13 receptor α2 during a T helper cell type 2- dominant immune response. J Exp Med, 2003, Vol. 197(6): 687–701
[110] Mentink-Kane MM, Cheever AW, Thompson RW, et al. IL-13 receptor α2 downmodulates granulomatous inflammation and prolongs host survival in schistosomiasis. Proc Natl Acad Sci USA, 2004, Vol. 101(2): 586–590
[111] Zheng T, Zhu Z, Liu W, et al. Cytokine regulation of IL-13Rα2 and IL-13Rα1 in vivo and in vitro. J Allergy Clin Immunol, 2003, Vol. 111(4): 720–728
[112] Jakubzick C, Choi ES, Kunkel SL, et al. Impact of interleukin-13 responsiveness on the synthetic and proliferative properties of TH1- and TH2-type pulmonary granuloma fibroblasts. Am J Pathol, 2003, Vol. 162(5): 1475–1486
[113] Daines MO, Hershey GK. A novel mechanism by which interferon-γ can regulate interleukin (IL)-13 responses. Evidence for intracellular stores of IL-13 receptor α-2 and their rapid mobilization by interferon-γ. J Biol Chem, 2002, Vol. 277(12): 10387–10393
[114] Wynn TA, Hesse M, Sandler NG, et al. P-selectin suppresses hepatic inflammation and fibrosis in mice by regulating interferon-γ and the IL-13 decoy receptor. Hepatology, 2004, Vol. 39(3): 676–687
[115] Clark JG, Dedon TF, Wayner EA, et al. Effects of interferon-γ on expression of cell surface receptors for collagen and deposition of newly synthesized collagen by cultured human lung fibroblasts. J Clin Invest, 1989, Vol. 83(5): 1505–1511
[116] Hansen G, Berry G, DeKruyff RH, et al. Allergen-specific TH1 cells fail to counterbalanceTH2 cellinduced airway hyperreactivity but cause severe airway inflammation. J Clin Invest, 1999, Vol. 103(2): 175–183
[117] Randolph DA, Stephens R, Carruthers CJ, et al. Cooperation between TH1 and TH2 cells in a murine model of eosinophilic airway inflammation. J Clin Invest, 1999, Vol. 104(8): 1021–1029
[118] Ford JG, Rennick D, Donaldson DD, et al. IL-13 and IFN-γ: interactions in lung inflammation. J Immunol, 2001, Vol. 167(3): 1769–1777
[119] Castro M, Chaplin DD, Walter MJ, et al. Could asthma be worsened by stimulating the T-helper type1 immune response? Am J Respir Cell Mol Biol, 2000, Vol. 22(2): 143–146
[120] Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science, 1998, Vol. 282(5397): 2258–2261
[121] Grunig G, Warnock M, Wakil AE, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science, 1998, Vol. 282(5397): 2261–2263
[122] Marth T, Strober W, Seder RA, et al. Regulation of transforming growth factor-β production by interleukin-12. Eur J Immunol, 1997, Vol. 27(5): 1213–1220
[123] Nelson DR, Lauwers GY, Lau JY, et al. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology, 2000, Vol. 118(4): 655–660
[124] Kaufman J, Sime PJ, Phipps RP. Expression of CD154 (CD40 ligand) by human lung fibroblasts: differential regulation by IFN-γ and IL-13, and implications for fibrosis. J Immunol, 2004, Vol. 172(3): 1862–1871
[125] Adawi A, Zhang Y, Baqqs R, et al. Blockade of CD40–CD40 ligand interactions protects against radiation-induced pulmonary inflammation and fibrosis. Clin Immunol Immunopathol, 1998, Vol. 89(3): 222–230
[126] Katsuma S, Nishi K, Taniqawara K, et al. Molecular monitoring of bleomycininduced pulmonary fibrosis by cDNA microarray-based gene expression profiling. Biochem Biophys Res Commun, 2001, Vol. 288(4): 747–751
[127] Kaminski N. Microarray analysis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol, 2003, Vol. 29(3 Suppl): S32–S36
[128] Anders RA, Yerian LM, Tretiakova M, et al. cDNA microarray analysis of macroregenerative and dysplastic nodules in end-stage hepatitis C virus-induced cirrhosis. Am J Pathol, 2003, Vol. 162(3): 991–1000
[129] Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature, 1996, Vol. 383(6603): 787–793
[1] Wynn TA. Fibrotic disease and the TH1/ TH2 paradigm. Nat Rev. Immunol, 2004, Vol. 4(8):583–594
[2] Sandler N G, Mentink-Kane M M, Cheever A, et al. Global gene expression profiles during acute pathogen-induced pulmonary inflammation reveal divergent roles for TH1 and TH2 responses in tissue repair. J Immunol, 2003, Vol. 171(7): 3655–3667
[3] Magalhaes A, Miranda DG, Miranda RG, et al. Cytokine profile associated with human chronic schistosomiasis mansoni. Mem Inst Oswaldo Cruz, 2004, Vol. 99(5 Suppl 1):21-26
[4] Mentink-Kane MM, Cheever AW, Thompson RW, et al. IL-13 receptor α2 downmodulates granulomatous inflammation and prolongs host survival in schistosomiasis. Proc Natl Acad Sci USA, 2004, Vol. 101(2): 586–590
[5] Chiaramonte M G, Cheever A W, Malley J D, et al. Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis. Hepatology, 2001, Vol. 34(2): 273–282
[6] Fulkerson PC, Fischetti CA, Hassman LM, et al. Persistent effects induced by IL-13 in the lung. Am J Respir Cell Mol Biol. 2006, Apr 27[Epub ahead of print]
[7] Oriente A, Fedarko NS, Pacocha SE, et al. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther, 2000, Vol. 292(3):988-994
[8] Fertin C, Nicolas JF, Gillery P, et al. Interleukin-4 stimulates collagen synthesis by normal and scleroderma fibroblasts in dermal equivalents. Cell Mol Biol, 1991, Vol. 37(8): 823–829
[9] Saito A, Okazaki H, Sugawara I, et al. Potential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro. Int Arch Allergy Immunol, 2003, Vol. 132(2): 168–176
[10] Walter DM, McIntire JJ, Berry G, et al. Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J Immunol, 2001, Vol. 167(8): 4668–4675
[11] Kumar RK, Herbert C, Yang M, et al. Role of interleukin-13 in eosinophil accumulation and airway remodelling in a mouse model of chronic asthma. Clin Exp Allergy, 2002, Vol. 32(7): 1104–1111
[12] Lee CG, Homer RJ, Zhu Z, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor β1. J Exp Med, 2001, Vol. 194(6): 809–821
[13] Lanone S, Zheng T, Zhu Z, et al. Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and –12 in IL-13-induced inflammation and remodeling. J Clin Invest,2002, Vol. 110(4): 463–474
[14] Kaviratne M, Hesse M, Leusink M, et al. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol, 2004, Vol. 173(6):4020-4029
[15] Liu T, Jin H, Ullenbruch M, et al. Regulation of found in inflammatory zone 1 expression in bleomycin-induced lung fibrosis: role of IL-4/IL-13 and mediation via STAT-6. J Immunol. 2004, Vol. 173(5):3425-3431
[16] Donnelly LE, Barnes PJ. Acidic mammalian chitinase--a potential target for asthma therapy. Trends Pharmacol Sci. 2004, Vol. 25(10):509-511
[17] Finkelman FD, Shea-Donohue T, Morris SC, et al. Interleukin-4 and interleukin-13-mediated host protection against intestinal nematode parasites. Immunol Rev, 2004, Vol. 201: 139-155
[18] Jinnin M, Ihn H, Yamane K, et al. Interleukin- 13 stimulates the transcription of the human alpha2(I) collagen gene in human dermal fibroblasts. J Biol Chem, 2004, Vol. 279(40):41783-41791
[19] Mentink-Kane MM, Wynn TA. Opposing roles for IL-13 and IL-13 receptor alpha 2 in health and disease. Immunol Rev, 2004, Vol. 202: 191-202
[20] Kaufman J, Sime P J, Phipps R P. Expression of CD154 (CD40 ligand) by human lung fibroblasts: differential regulation by IFN-γ and IL-13, and implications for fibrosis. J. Immunol, 2004, Vol. 172: 1862–1871
[2] 高春芳,陆伦根. 纤维化疾病的基础和临床. 第一版. 上海: 上海科学技术出版社, 2004: 199-201
[3] Marneros AG, Krieg T. Keloids--clinical diagnosis, pathogenesis, and treatment options. J Dtsch Dermatol Ges, 2004, Vol. 2(11):905-913
[4] Slemp AE, Kirschner RE. Keloids and scars: a review of keloids and scars, their pathogenesis, risk factors, and management. Curr Opin Pediatr, 2006, Vol. 18(4): 396-402
[5] Ala-Kokko L, Rintala A, Savolainen ER. Collagen gene expression in keloids: analysis of collagen metabolism and type I, III, IV, and V procollagen mRNAs in keloid tissue and keloid fibroblast culture. J Invest Dermatol, 1987, Vol. 89(3): 238-244
[6] Abergel RP, Pizzurro D, Meeker CA, et al. Biochemical composition of the connective tissue in keloids and analysis of collagen metabolism in keloid fibroblasts cultures. J Invest Dermatol, 1985, Vol. 84(5): 384-390
[7] Wynn TA. Fibrotic disease and the TH1/ TH2 paradigm. Nat Rev Immunol, 2004, Vol. 4(8):583-594
[8] Gurujeyalakshmi G, Giri SN. Molecular mechanisms of antifibrotic effect of interferon-γ i?n bleomycin-mouse model of lung fibrosis: downregulation of TGF-β a?nd procollagen I and III gene expression. Exp Lung Res, 1995, Vol. 21(5): 791-808
[9] Cho JY, Miller M, Baek KJ, et al. Inhibition of airway remodeling in IL-5-deficient mice. J. Clin. Invest, 2004, Vol. 113(4): 551–560
[10] Huaux F, Liu T, Mcgarry B, et al. Eosinophils and T lymphocytes possess distinct roles in bleomycin-induced lung injury and fibrosis. J Immunol, 2003, Vol. 171(10): 5470–5481
[11] Nelson DR, Tu Z, Soldevila-Pico C, et al. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology, 2003, Vol. 38(4): 859–868
[12] Hesse M, Piccirillo CA, Belkaid Y, et al. The pathogenesis of schistosomiasis is controlled by cooperating IL-10-producing innate effector and regulatory T cells. J Immunol, 2004, Vol. 172(5): 3157–3166
[13] Lee CG, Homer RJ, Cohn L, et al. Transgenic overexpression of interleukin (IL)-10 in the lung causes mucus metaplasia tissue inflammation, and airway remodeling via IL-13-dependent and -independent pathways. J Biol Chem, 2002, Vol. 277(38): 35466–35474
[14] Hoffmann KF, McLarty TC, Seqal DH, et al. Disease fingerprinting with cDNA microarraysreveals distinct gene expression profiles in lethal type 1 and type 2 cytokine-mediated inflammatory reactions. FASEB J, 2001, Vol. 15(13): 2545-2547
[15] Sandler NG., Mentink-Kane MM., Cheever A, et al. Global gene expression profiles during acute pathogen-induced pulmonary inflammation reveal divergent roles for TH1 and TH2 responses in tissue repair. J Immunol, 2003, Vol. 171(7): 3655-36674
[16] Brazova J, Sediva A, Pospisilova D, et al. Differential cytokine profile in children with cystic fibrosis. Clin Immunol, 2005, Vol. 115(2):210-215
[17] Pacanowski MA, Amsden GW. Interferon Gamma-1b in the Treatment of Idiopathic Pulmonary Fibrosis (October). Ann Pharmacother. 2005, Vol. 39(10):1678-1686
[18] Oldroyd SD, Thomas GL, Gabbiani G, et al. Interferon-γ ?inhibits experimental renal fibrosis. Kidney Int, 1999, Vol. 56(6): 2116-2127
[19] Jordana M, Ohna I, Xing Z, et al. Cytokines in lung and airways fibrosis. Reg Immunol. 1993, Vol. 5(3-4):201-206
[20] Magalhaes A, Miranda DG, Miranda RG, et al. Cytokine profile associated with human chronic schistosomiasis mansoni. Mem Inst Oswaldo Cruz, 2004, Vol. 99(5 Suppl 1):21-26
[21] Keane MP, Belperio JA, Burdick MD, et al. IL-12 attenuates bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell. Mol. Physiol. 2001, Vol. 281(1): L92-L97
[22] Sempowski GD, Beckmann MP, Derdak S, et al. Subsets of murine lung fibroblasts express membrane-bound and soluble IL-4 receptors. Role of IL-4 in enhancing fibroblast proliferation and collagen synthesis. J Immunol, 1994, Vol. 152(7): 3606-3614
[23] Lee CG, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor β1. J Exp Med, 2001, Vol. 194(6): 809-821
[24] Sheppard D. Transforming growth factor beta: a central modulator of pulmonary and airway inflammation and fibrosis. Proc Am Thorac Soc, 2006, Vol. 3(5):413-417
[25] Roberts AB, Russo A, Felici A, et al. Smad3: a key player in pathogenetic mechanisms dependent on TGF-β. Ann NY Acad Sci, 2003, Vol. 995: 1–10
[26] Wang S, Hirschberg R. BMP7 antagonizes TGF-β-dependent fibrogenesis in mesangial cells. Am. J. Physiol. Renal Physiol, 2003, Vol. 284(5): F1006–F1013
[27] Ma LJ, Yang H, Gaspert A, et al. Transforming growth factor-β-dependent and -independent pathways of induction of tubulointerstitial fibrosis in β6–/– mice. Am. J. Pathol, 2003, Vol. 163(4):1261–1273
[28] Zhang T, Rong XZ, Yang RH, et al. Effect of asiaticoside on the expression of transforming growth factor-beta mRNA and matrix metalloproteinases in hypertrophic scars. Nan Fang Yi Ke Da Xue Xue Bao, 2006, Vol. 26(1):67-70
[29] Wynn T A. IL-13 effector functions. Annu Rev Immunol, 2003, Vol. 21: 425-456
[30] Brown KD, Zurawski SM, Mosmann TR, et al. A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes. J Immunol, 1989, Vol. 142(2): 679-687
[31] Minty A, Chalon P, Derocq JM, et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature, 1993, Vol. 362(6417): 248-250
[32] Mckenzie A N J, Culpepper J A, Walefyt R D, et al. Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc Natl Acad Sci USA, 1993, Vol. 90: 3735-3739
[33] Mentink-Kane MM, Cheever AW, Thompson RW, et al. IL-13 receptor α2 downmodulates granulomatous inflammation and prolongs host survival in schistosomiasis. Proc Natl Acad Sci USA, 2004, Vol. 101(2): 586-590
[34] Wood N, Whitters MJ, Jacobson BA, et al. Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor α2. Exp Med, 2003, Vol. 197(6): 703–709.
[35] Jakubzick C, Choi ES, Kunkel SL, et al. Impact of interleukin-13 responsiveness on the synthetic and proliferative properties of TH1- and TH2-type pulmonary granuloma fibroblasts. Am J Pathol, 2003, Vol. 162(5), 1475–1486
[36] Chiaramonte MG., Cheever AW, Malley JD, et al. Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis. Hepatology, 2001, Vol. 34(2): 273-282
[37] Jakubzick C, Kunkel SL, Puri RK, et al. Therapeutic targeting of IL-4- and IL-13-responsive cells in pulmonary fibrosis. Immunol Res, 2004, Vol. 30(3): 339-349
[38] Elias JA, Kang MJ, Crouthers K, et al. State of the art. Mechanistic heterogeneity in chronic obstructive pulmonary disease: insights from transgenic mice. Proc Am Thorac Soc. 2006, Vol. 3(6):494-498
[39] Fulkerson PC, Fischetti CA, Hassman LM, et al. Persistent effects induced by IL-13 in the lung. Am J Respir Cell Mol Biol. 2006, Vol. 35(3):337-346
[40] Jiang H, Harris MB, Rothman P. IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol. 2000, Vol. 105(6):1063-1070
[41] Kelly-Welch A, Hanson EM, Keegan AD. Interleukin-13 (IL-13) pathway. Sci STKE, 2005 Jul 19, 2005(293):cm8
[42] Fertin C, Nicolas JF, Gillery P, et al. Interleukin-4 stimulates collagen synthesis by normal and scleroderma fibroblasts in dermal equivalents. Cell Mol Biol, 1991, Vol. 37(8): 823-829
[43] Zurawski SM, Vega F Jr, Huyghe B, et al. Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J, 1993, Vol. 12(7): 2663-2670
[44] Saito A, Okazaki H, Sugawara I, et al. Potential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro. Int Arch. Allergy Immunol, 2003, Vol. 132(2): 168-176
[45] Webb DC, McKenzie AN, Koskinen AM, et al. Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. J Immunol, 2000, Vol. 165(1): 108-113
[46] Walter DM, McIntire JJ, Berry G, et al. Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J Immunol, 2001, Vol. 167(8): 4668-4675
[47] Fallon PG, Richardson EJ, McKenzie GJ, et al. Schistosome infection of transgenic micedefines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. J Immunol, 2000, Vol. 164(5): 2585-2591
[48] Kumar RK, Herbert C, Yang M, et al. Role of interleukin-13 in eosinophil accumulation and airway remodelling in a mouse model of chronic asthma. Clin Exp Allergy, 2002, Vol. 32(7): 1104-1111
[49] Oriente A, Fedarko NS, Pacocha SE, et al. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther, 2000, Vol. 292(3):988-994
[50] Lanone S, Zheng T, Zhu Z, et al. Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and –12 in IL-13-induced inflammation and remodeling. J Clin Invest, 2002, Vol. 110(4): 463-474
[51] Kaviratne M, Hesse M, Leusink M, et al. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol, 2004, Vol. 173(6):4020-4029
[52] Obiri NI, Debinski W, Leonard WJ, et al. Receptor for interleukin 13 interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem, 1995, Vol. 270(15):8797-8804
[53] Mentink-Kane MM, Wynn TA. Opposing roles for IL-13 and IL-13 receptor alpha 2 in health and disease. Immunol Rev, 2004, Vol. 202: 191-202
[54] Arima K, Sato K, Tanaka G, et al. Characterization of the interaction between interleukin-13 and interleukin-13 receptors. J Biol Chem, 2005, Vol. 280(26):24915-24922
[55] Murata T, Husain SR, Mohri H, et al. Two different IL-13 receptor chains are expressed in normal human skin fibroblasts, and IL-4 and IL-13 mediate signal transduction through a common pathway. Int Immunol, 1998, Vol. 10(8):1103-1110
[56] Kelly-Welch AE , Hanson EM ,et al. Interleukin-4 and interleukin-13 signaling connections maps. Science, 2003, Vol. 300(6):1527-1528
[57] Hershey GK. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol. 2003, Vol. 111(4):677-690
[58] Ingram GL, Antao-Menezes A, Mangum JB, et al. Opposing actions of Stat1 and Stat6 on IL-13-induced up-regulation of early growth response-1 and platelet-derived growth factor ligands in pulmonary fibroblasts. J Immunol, 2006, Vol. 177(6):4141-4148
[59] Palmqvist P, Lundberg P, Persson E, et al. Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway. J Biol Chem, 2006, Vol. 281(5): 2414-2429
[60] Cordula B, Annett S, Ernst P R.. Transcriptional activation of the type I collagen genes COL1A1 and COL1A2 in fibroblasts by interleukin-4: analysis of the functional collagen promoter sequences. J Cell Physiol, 2004, Vol. 198(2): 248-258
[61] Tracy L M, Maithao L, Takao K, et al. Molecular mechanisms of interleukin-4-induced up-regulation of type I collagen gene expression in murine fibroblasts. Arthritis Rheumatis, 2003, Vol. 48(8): 2275-2284
[62] Granstein RD, Flotte TJ, Amento EP. Interferons and collagen production. J Invest Dermatol, 1990, Vol. 95(6 Suppl): 75S-80S
[63] Cen Y, Yan XR. Effect of gamma-interferon on the fibroblasts in hypertrophic scars. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, 1999, Vol. 13(2): 122-126
[64] Kim WJ. Cellular signaling in tissue regeneration. Yonsei Med J, 2000, Vol. 41(6): 692-703
[65] Joshi BH, Hogaboam C, Dover P, et al. Role of interleukin-13 in cancer, pulmonary fibrosis, and other T(H)2-type diseases. Vitam Horm 2006, Vol. 74: 479-504
[66] 高春芳. 胶原基因转录调控与纤维化. 世界华人消化杂志, 2005, 13(2): 166-171
[67] Wu J, Reinhardt DP, Batmunkh C, et al. Functional diversity of lysyl hydroxylase 2 in collagen synthesis of human dermal fibroblasts. Exp Cell Res, 2006, Vol. 312 (18): 3485-3494
[68] Gharaee-Kermani M, Phan SH. Molecular mechanisms of and possible treatment strategies for idiopathic pulmonary fibrosis. Curr Pharm Des, 2005, Vol. 11(30):3943-3971
[69] Bataller R, Brenner DA. Liver fibrosis. J Clin Invest, 2005, Vol. 115(2):209-218
[70] 司徒镇强, 吴军正主编. 细胞培养第一版. 北京:世界图书出版社, 2001. 43-57
[71] 鄂征等主编. 组织培养和分子细胞学技术. 北京:北京出版社, 1995. 120-138
[72] 萨姆布鲁克 J,弗里奇 E.F,曼尼阿蒂斯 T 主编. 分子克隆实验指南第三版. 北京:科学出版社, 2003. 385-455; 1681-1727
[73] 奥斯伯 F,布伦特 R,金斯顿 R E 主编. 精编分子生物学实验指南. 北京:科学出版社, 2003. 329-373
[74] 汪家政,范明主编. 蛋白质技术手册. 上海:科学出版社, 2001. 166-184
[75] Kaufman J, Sime PJ, Phipps RP. Expression of CD154 (CD40 ligand) by human lung fibroblasts: differential regulation by IFN-γ and IL-13, and implications for fibrosis. J Immunol, 2004, Vol. 172(3): 1862-1871
[76] Tsukada S, Westwick JK, Ikejima K, et al. SMAD and p38 MAPK signaling pathways independently regulate alpha1(I) collagen gene expression in unstimulated and transforming growth factor-beta-stimulated hepatic stellate cells. J Biol Chem, 2005, Vol. 280(11):10055-10064
[77] Higashi K, Inagaki Y, Fujimori K, et al. Interferon-gamma interferes with transforming growth factor-beta signaling through direct interaction of YB-1 with Smad3. J Biol Chem, 2003, Vol. 278(44):43470-43479
[78] Ramirez F, Tanaka S, Bou-Gharios G. Transcriptional regulation of the human alpha2(I) collagen gene (COL1A2), an informative model system to study fibrotic diseases. Matrix Biol, 2006, Vol. 25(6):365-372
[79] Gao CF, Wang H, Wang AH, et al. Transcriptional regulation of human alpha1(I) procollagen gene in dermal fibroblasts. World J Gastroenterol, 2004, Vol. 10(10): 1447-1451
[80] Lindahl GE, Chambers RC, Papakrivopoulou J, et al. Activation of fibroblast procollagen alpha 1(I) transcription by mechanical strain is transforming growth factor-beta-dependent and involves increased binding of CCAAT-binding factor (CBF/NF-Y) at the proximalpromoter. J Biol Chem, 2002, Vol. 277(8):6153-6161
[81] Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest, 1999, Vol. 103(6):779-788
[82] Chiaramonte MG, Donaldson DD, Cheever AW, et al. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest, 1999, Vol. 104(6):777-785
[83] Kolodsick JE, Toews GB, Jakubzick C,et al. Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts. J Immunol, 2004, Vol. 172(7):4068-4076
[84] Jinnin M, Ihn H, Asano Y, et al. Upregulation of tenascin-C expression by IL-13 in human dermal fibroblasts via the phosphoinositide 3-kinase/Akt and the protein kinase C signaling pathways. J Invest Dermatol, 2006, Vol. 126(3):551-560
[85] Jinnin M, Ihn H, Yamane K, et al. Interleukin- 13 stimulates the transcription of the human alpha2(I) collagen gene in human dermal fibroblasts. J Biol Chem, 2004, Vol. 279(40):41783-91
[86] Zhou X, Hu H, Huynh ML, et al. Mechanisms of tissue inhibitor of metalloproteinase 1 augmentation by IL-13 on TGF-beta1-stimulated primary human fibroblasts. J Allergy Clin Immunol, 2007 Apr 4; [Epub ahead of print]
[87] Fichtner-Feigl S, Strober W, Kawakami K, et al. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med, 2006, Vol. 12(1): 99-106
[88] Benekli MB, Baer MR, Baumann H, et al. Signal transducer and activator of transcription proteins in leukemias. Blood, 2003, Vol. 101(8): 2940-2950
[89] 杨洁,姚智等. 人p100蛋白:可增强STAT6基因转录活性的新因子. 中国免疫学杂志, 2004, 20(11):739-742
[90] Calo V , Migliavacca M, Bazan V,et al. STAT proteins: from normal control of cellular events to tumorigenesis. J Cellular Physiol, 2003, Vol. 197(2):157–168
[91] Daines MO, Andrews RP, Chen WG, et al. DNA binding activity of cytoplasmic phosphorylated Stat6 is masked by an interaction with a detergent-sensitive factor. J Biol Chem, 2003, Vol. 278(33): 30971-30974
[92] 叶乐平.信号转导子和转录激活子 6 与支气管哮喘.国外医学儿科学分册, 2003, 9(5):234-236.
[93] Chen W, Daines Mo, Hershey GK. Methylation of STAT6 modulates STAT6 phosphorylation, nuclear translocation, and DNA-binding activity. J Immunol, 2004, Vol. 172(11):6744-6750
[94] Malefyt RDW, Figdor CG, Huijbens R, et al. Effects of IL-13 on phenotype,cytokine production, and cytotoxic function of human monocytes. J Immunol, 1993, Vol. 151: 6370-6381
[95] Yoshikawa M, Nakajima T, Tsukidate T, et al. TNF-alpha and IL-4 regulate expression of IL-13 receptor alpha2 on human fibroblasts. Biochem Biophys Res Commun, 2003, Vol. 312(4):1248-55
[96] Kato A, Kawamata N, Tamayose K, et al. Ancient ubiquitious protein 1 binds to the conserved membrane-proximal sequence of the cytoplasmic tail of the integrin α subunits that plays a crucial role in the inside-out signaling of αIIbβ3. J Biol Chem, 2002, Vol. 277(32): 28934-28941
[97] Orchansky PL, Kwan R, Lee F, et al. Characterization of the cytoplasmic domain of Interleukin-13 receptor-α. J Bio Chem, 1999, Vol. 274(30):20818-20825
[98] Zhang JG, Hilton DJ , et al. Identification, purification, and characterization of a soluble interleukin(IL)-13-binding protein. J Biol Chem, 1997, Vol. 272(14):9474- 9480
[99] Murata T, Obiri NI, Debinski W, et al. Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem Biophys Res Commun, 1997, Vol. 238(1):90-94
[100] David M, Ford D, Bertoglio J, et al. Induction of the IL-13 receptor α2-chain by IL-4 and IL-13 in human keratinocytes: involvement of STAT6, ERk and p38 MAPK pathways. Oncogene, 2001, Vol. 20 (46):6660-6668
[101] Donnelly LE, Barnes PJ,et al. Acidic mammalian chitinase--a potential target for asthma therapy. Trends Pharmacol Sci, 2004, Vol. 25(10):509-511
[102]Guiter C, Dusanter-Fourt I, Copie-Bergman C,et al. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood, 2004, Vol. 104(2):543-549
[103]Finkelman FD, Shea-Donohue T, Morris SC. Interleukin-4 and interleukin-13-mediated host protection against intestinal nematode parasites. Immunol Rev, 2004, Vol. 201:139-55
[104]Liu T, Jin H, Ullenbruch M, et al. Regulation of found in inflammatory zone 1 expression in bleomycin-induced lung fibrosis: role of IL-4/IL-13 and mediation via STAT-6. J Immunol, 2004, Vol. 173(5):3425-3431
[105]Hoeck J, woisetschlager M. Activation of eotaxin-3/CCLl26 gene expression in human dermal fibroblasts is mediated by STAT6.J Immunol, 2001, Vol. 167(6):3216-3222
[106]Hebenstreit D, Wirnsberger G, Horejs-Hoech J, et al. Signaling mechanisms, interaction partners, and target genes of STAT6. Cytokine Growth Factor Rev, 2006, Vol.17(3):173-88
[107]Andrews RP, Ericksen MB, Cunningham CM, et al. Analysis of the life cycle of Stat6. J Biol Chem, 2002, Vol. 277(39):36563-36569
[108]Losman JA, Chen XP, Hilton D, et al. Cutting Edge: SOCS-1 is a potent inhibitor of IL-4 signal transduction. J Immunol, 1999, Vol. 162(7): 3770-3774
[109]Hanson EM,Dickensheets H,QU CK, et al. Regulation of the dephosphorylation of Stat6. J Biol Chem, 2003, Vol. 278(6):3903-3911
[110]Andrews AL, Holloway JW, Puddicombe SM. Kinetic analysis of the interleukin-13 receptor complex. J Biol Chem, 2002, Vol. 277(48): 46073-46078
[111]Shuai K. Modulation of STAT signaling by STAT-interacting proteins. Oncogene, 2000, Vol.19(21): 2638-2644
[112]V?lineva T, Yang J, Palovuori R, et al. The transcriptional co-activator protein p100 recruits histone acetyltransferase activity to STAT6 and mediates interaction between the CREB-binding protein and STAT6. J Biol Chem, 2005, Vol. 280(15): 14989–14996
[113]Popescu FD. New asthma drugs acting on gene expression. J Cell Mol Med, 2003, Vol. 7(4):475-486
[114]Bennett BL, Cruz R, lacson RG, et al. Interleukin-4 suppression of tumor necrosis factor -stimulated E-selectin gene transcription is mediated by STAT6 antagonism of NF- B. J Biol Chem, 1997, Vol. 272(15):10212-10219
[115]Wurster AL, Rodgers VL, White MF, et al. Interleukin-4-mediated protection of primary B cells from apoptosis through Stat6-dependent up-regulation of Bcl-xL. J Biol Chem, 2002, Vol. 277(30):27169-27175
[116]Bhogal RK, Stoica CM, McGaha TL, et al. Molecular aspects of regulation of collagen gene expression in fibrosis. J Clin Immunol, 2005, Vol. 25(6): 592-603
[117]Cobb MH.MAP kinase pathways.Prog Biophys Mol Biol.1999, Vol. 71(3-4): 479-500
[118]Ruckemann K, Fairbanks LD, Carrey EA, et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem, 1998, Vol. 273 (34): 21682-21691.
[119]Mattar T, Kochhar K, Bartlett R, et al. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett, 1993, Vol. 334(2):161-164
[120]Klausner RD, Samelson LE. T cell antigen receptor activation pathway; the tyrosine kinase connection. Cell, 1991, Vol. 64(5):875-878
[121]Tomita N, Morishita R, Lan HY, et al. In vivo administration of a nuclear transcription factor-kappaB decoy suppresses experimental crescentic glomerulonephritis. J Am Soc Nephrol, 2000, Vol. 11(7):124-129
[122]Siemasko K, Chong A S, Jack HM , et al. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immuno suppressive drug leflunomide leads to block in IgG1 production. J Immunol,1998, 160 (4) : 1581-1588
[123]Fox RI, Herrmann ML, Frangou CG, et al. Mechanism of action for leflunomide in arthritis. Clin Immunol, 1999, Vol. 93 (3): 198-208
[124]Xu X, Williams JW, Gong H, et al. Two activities of the immunosuppressive metabolite of leflunomide, A77 1726 Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Biochem Pharmacol, 1996, Vol. 52(4):527-534
[125]SIEMASKO K,CHONG AS , JACK HM , et al . Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosup2 pressive drug leflunomide leads to a block in IgG1 production. J Immuonol, 1998, Vol. 160 (4) : 1581-1588
[126]Jarman ER, Kuba A, Montermann E, et al. Inhibition of murine IgE and immediate cutaneous hypersensitivity responses to ovalbumin by the immunomodulatory agent leflunomide. Clin Exp Immunol, 1999, Vol. 115 (2): 2212-2228
[127]Kraan MC, Reece RJ, Barg EC, et al. Modulation of inflammation and metallopteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Arthritis Rheum, 2000, Vol. 42 (8): 1820-1830
[128]Si HF, Li J, Lu XW, et al. Suppressive effects of leflunomide on leptin-induced collagen I involved in hepatic stellate cell proliferation. Exp Biol Med (Maywood), 2007, Vol. 232(3): 427-436
[129]Yao HW, Li J, Chen JQ, et al. Inhibitory effect of leflunomide on hepatic fibrosis induced by CCl4 in rats. Acta Pharmacol Sin, 2004, Vol. 25(7): 915-920
[130]姚宏伟,李俊,陈季强,等.来氟米特对肝星状细胞增殖和胶原合成的影响.浙江大学学报(医学版), 2004, 33(6): 515-518
[131]Akiho H, Lovato P, Deng Y, et al. Interleukin-4- and -13-induced hypercontractility of human intestinal muscle cells-implication for motility changes in Crohn's disease. Am J Physiol Gastrointest Liver Physiol, 2005, Vol. 288(4): G609- G615
[132]Kagami S,Saeki H.Interleukin-4 and interleukin-13 enhance CCL26 production in a human keratinocyte cell line, HaCaT cells. Inflamm Res, 2006, Vol. 55(11):469-475.
[133]Latchoumycandane C, Seah QM, Leflunomide or A77 1726 protect from -induced cell injury through inhibition of JNK-mediated mitochondrial permeability transition in immortalized human hepatocytes. Glycobiology, 1996, Vol. 6(4):399-406
[134]Tredget EE, Yang L, Delehanty M, et al. Polarized Th2 cytokine production in patients with hypertrophic scar following thermal injury. J Interferon Cytokine Res, 2006, Vol. 26(3): 179-189
[135]Tredget EE, Wang R, Shen Q, et al. Transforming growth factor-beta mRNA and protein in hypertrophic scar tissues and fibroblasts: antagonism by IFN-alpha and IFN-gamma in vitro and in vivo. J Interferon Cytokine Res, 2000, Vol. 20(2): 143-151
[136]Aliprantis AO, Wang J, Fathman JW, et al. Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci U S A. 2007, Vol. 104(8): 2827-2830.
[137]Lakos G, Melichian D, Wu M, et al. Increased bleomycin-induced skin fibrosis in mice lacking the Th1-specific transcription factor T-bet. Pathobiology, 2006, Vol. 73(5): 224-237
[138]Grassegger A, Hopfl R. Significance of the cytokine interferon gamma in clinical dermatology. Clin Exp Dermatol, 2004, Vol. 29(6): 584-588
[139]Pittet B, Rubbia-Brandt L, Desmouliere A, et a1. Effect of gamma-interferon on the clinical and biologic evolution of hypertrophic scars and Dupuytren's disease: an open pilot study. P1ast Reconstr Surg, 1994, Vol. 93(6): 1224-1235
[1] Wynn TA. Fibrotic disease and the TH1/ TH2 paradigm. Nature Rev Immunol,2004, Vol. 4(8): 583–594
[2] Wynn TA, Cheever AW, Jankovic D, et al. An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature, 1995, Vol. 376(6541): 594–596
[3] Hoffmann KF, Cheever AW, Wynn TA. IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis. J Immunol, 2000, Vol. 164(12): 6406–6416
[4] Gurujeyalakshmi G, Giri SN. Molecular mechanisms of antifibrotic effect of interferon-γ i?n bleomycin-mouse model of lung fibrosis: downregulation of TGF-β a?nd procollagen I and III gene expression. Exp Lung Res, 1995, Vol. 21(5): 791–808
[5] Keane MP, Belperio JA, Burdick MD, et al. IL-12 attenuates bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol, 2001, Vol. 281(1): L92–L97
[6] Oldroyd SD, Thomas GL, Gabbiani G, et al. Interferon-gamma i?nhibits experimental renal fibrosis. Kidney Int, 1999, Vol. 56(6): 2116–2127
[7] Poynard T, Yuen MF, Ratziu V, et al. Viral hepatitis C. Lancet, 2003, Vol. 362(9401): 2095–2100
[8] Hesse M, Cheever AW, Jankovic D, et al. NOS-2 mediates the protective anti-inflammatory and antifibrotic effects of the TH1-inducing adjuvant, IL-12, in a TH2 model of granulomatous disease. Am J Pathol, 2000, Vol. 157(3): 945–955
[9] Hoffmann KF, McLarty TC, Seqal DH, et al. Disease fingerprinting with cDNA microarrays reveals distinct gene expression profiles in lethal type 1 and type 2 cytokine-mediated inflammatory reactions. FASEB J, 2001, Vol. 15(13): 2545–2547
[10] Sandler NG, Mentink-Kane MM, Cheever AW, et al. Global gene expression profiles during acute pathogen-induced pulmonary inflammation reveal divergent roles for TH1 and TH2 responses in tissue repair. J Immunol, 2003, Vol. 171(7): 3655–3667
[11] Walker LS, Abbas AK. The enemy within: keeping self-reactive T cells at bay in the periphery. Nature Rev Immunol, 2002, Vol. 2(1): 11–19
[12] Hesse M, Modolell M, La Flamme AC, et al. Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism. J Immunol, 2001, Vol. 167(11): 6533–6544
[13] Decitre M, Gleyzal C, Raccurt M, et al. Lysyl oxidase-like protein localizes to sites of de novo fibrinogenesis in fibrosis and in the early stromal reaction of ductal breast carcinomas. Lab Invest, 1998, Vol. 78(2): 143–151
[14] Wang S, Hirschberg R. BMP7 antagonizes TGF-β-dependent fibrogenesis in mesangial cells. Am J Physiol Renal Physiol. 2003, Vol. 284(5): F1006–F1013
[15] Underwood DC, Osborn RR, Bochnowicz S, et al. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol. 2000, Vol. 279(5): L895–L902
[16] Kim H, Oda T, Lopez-Guisa J, et al. TIMP-1 deficiency does not attenuate interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol, 2001, Vol. 12(4): 736–748
[17] Vaillant B, Chiaramonte M, Cheever AW, et al. Regulation of hepatic fibrosis and extracellular matrix genes by the TH response: new insight into the role of tissue inhibitors of matrix metalloproteinases. J Immunol, 2001, Vol. 167(12): 7017–7026
[18] Kaminski N, Allard JD, Pittet JF, et al. Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis. Proc Natl Acad Sci USA , 2000, Vol. 97(4): 1778–1783
[19] Kristensen DB, Kawada N, Imamura K, et al. Proteome analysis of rat hepatic stellate cells. Hepatology, 2000, Vol. 32(2): 268–277
[20] Emura M, Naqai S, TaKeuchi M, et al. In vitro production of B cell growth factor and B cell differentiation factor by peripheral blood mononuclear cells and bronchoalveolar lavage T lymphocytes from patients with idiopathic pulmonary fibrosis. Clin Exp Immunol, 1990, Vol. 82(1): 133–139
[21] Wallace WA, Ramage EA, Lamb D, et al. A type 2 (TH2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA). Clin Exp Immunol, 1995, Vol. 101(3): 436–441
[22] Booth M, Mwatha JK, Joseph S, et al. Periportal fibrosis in human Schistosoma mansoni infection is associated with low IL-10, low IFN-γ, high TNF-α, or low RANTES, depending on age and gender. J. Immunol, 2004, Vol. 172(2): 1295–1303
[23] Buttner C, Skupin A, Reimann T, et al. Local production of interleukin-4 during radiation-induced pneumonitis and pulmonary fibrosis in rats: macrophages as a prominent source of interleukin-4. Am J Respir Cell Mol Biol, 1997, Vol. 17(3): 315–325
[24] Fertin C, Nicolas JF, Gillery P, et al. Interleukin-4 stimulates collagen synthesis by normal and scleroderma fibroblasts in dermal equivalents. Cell Mol Biol, 1991, Vol. 37(8): 823–829
[25] Letterio JJ, Roberts AB. Regulation of immune responses by TGF-β. Annu Rev Immunol,1998, Vol. 16: 137–161
[26] Sempowski GD, Beckmann MP, Derdak S, et al. Subsets of murine lung fibroblasts express membrane-bound and soluble IL-4 receptors. Role of IL-4 in enhancing fibroblast proliferation and collagen synthesis. J Immunol, 1994, Vol. 152(7): 3606–3614
[27] Doucet C, Brouty-Boye D, Pottin-ClemenceauC, et al. Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. J Clin Invest , 1998, Vol. 101(10): 2129–2139
[28] Tiggelman AM, Boers W, Linthorst C, et al. Collagen synthesis by human liver (myo)fibroblasts in culture: evidence for a regulatory role of IL-1β, IL-4, TGF-β and IFN-γ. J Hepatol, 1995, Vol. 23(3): 307–317
[29] Cheever AW, Williams ME, Wynn TA, et al. Anti-IL-4 treatment of Schistosoma mansoni-infected mice inhibits development of T cells and non-B, non-T cells expressing TH2 cytokines while decreasing egg-induced hepatic fibrosis. J Immunol, 1994, Vol. 153(2): 753–759
[30] Ong C, Wong C, Roberts CR, et al. Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol, 1998, Vol. 28(9): 2619–2629
[31] Le MA, Flamand V, Demoor FX, et al. Critical roles for IL-4, IL-5, and eosinophils in chronic skin allograft rejection. J Clin Invest, 1999, Vol. 103(12): 1659–1667
[32] Zurawski SM, Vega F Jr, Huyghe B, et al. Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J, 1993, Vol. 12(7): 2663–2670
[33] McKenzie GJ, Emson CL, Bell SE, et al. Impaired development of TH2 cells in IL-13-deficient mice. Immunity, 1998, Vol. 9(3): 423–432
[34] Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest, 1999, Vol. 103(6): 779–788
[35] Donaldson DD, Whitters MJ, Fitz LJ, et al. The murine IL-13 receptor α2: molecular cloning, characterization, and comparison with murine IL-13 receptor α1. J Immunol, 1998, Vol. 161(5): 2317–2324
[36] Chiaramonte MG, Donaldson DD, Cheever AW, et al. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest, 1999, Vol. 104(6): 777–785
[37] Blease K, Jakubzick C, Westwick J, et al. Therapeutic effect of IL-13 immunoneutralization during chronic experimental fungal asthma. J Immunol, 2001, Vol. 166(8): 5219–5224
[38] Kumar RK, Herbert C, Yang M, et al. Role of interleukin-13 in eosinophil accumulation and airway remodelling in a mouse model of chronic asthma. Clin Exp Allergy, 2002, Vol. 32(7): 1104–1111
[39] Chiaramonte MG, Cheever AW, Malley JD, et al. Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis. Hepatology, 2001, Vol. 34(2): 273–282
[40] Fallon PG, Richardson EJ, McKenzie GJ, et al. Schistosome infection of transgenic micedefines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. J Immunol, 2000, Vol. 164(5): 2585–2591
[41] Belperio JA, Dy M, Burdick MD, et al. Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol, 2002, Vol. 27(4): 419–427
[42] Rankin JA, Picarella DE, Geba GP, et al. Phenotypic and physiologic characterization of transgenic mice expressing interleukin 4 in the lung: lymphocytic and eosinophilic inflammation without airway hyperreactivity. Proc Natl Acad Sci USA, 1996, Vol. 93(15): 7821–7825
[43] Murata T, Husain SR, Mohri H, et al. Two different IL-13 receptor chains are expressed in normal human skin fibroblasts, and IL-4 and IL-13 mediate signal transduction through a common pathway. Int Immunol, 1998, Vol. 10(8): 1103–1110
[44] Oriente A, Fedarko NS, Pacocha SE, et al. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther, 2000, Vol. 292(3): 988–994
[45] Saito A, Okazaki H, Sugawara I, et al. Potential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro. Int Arch Allergy Immunol, 2003, Vol. 132(2): 168–176
[46] Blease K, Schuh JM, Jakubzick C, et al. Stat6-deficient mice develop airway hyperresponsiveness and peribronchial fibrosis during chronic fungal asthma. Am J Pathol, 2002, Vol. 160(2): 481–490
[47] Webb DC, McKenzie AN, Koskinen AM, et al. Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. J Immunol, 2000, Vol. 165(1): 108–113
[48] Walter DM, McIntire JJ, Berry G, et al. Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J Immunol, 2001, Vol. 167(8): 4668–4675
[49] Webb DC, Mahalinqam S, Cai Y, et al. Antigen-specific production of interleukin (IL)-13 and IL-5 cooperate to mediate IL-4Rα-independent airway hyperreactivity. Eur J Immunol, 2003, Vol. 33(12): 3377–3385
[50] Gharaee-Kermani M, Phan SH. Lung interleukin-5 expression in murine bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol, 1997, Vol. 16(4): 438–447
[51] Sher A, Coffman RL, Heiny S, et al. Interleukin 5 is required for the blood and tissue eosinophilia but not granuloma formation induced by infection with Schistosoma mansoni. Proc Natl Acad Sci USA, 1990, Vol. 87(1): 61–64
[52] Hao H, Cohen DA, Jennings CD, et al. Bleomycin-induced pulmonary fibrosis is independent of eosinophils. J Leukoc Biol, 2000, Vol. 68(4): 515–521
[53] Gharaee-Kermani M, McGatty B, Lukaca N, et al. The role of IL-5 in bleomycininduced pulmonary fibrosis. J Leukoc Biol, 1998, Vol. 64(5): 657–666
[54] Blyth DI, Wharton TF, Pedrick MS, et al. Airway subepithelial fibrosis in a murine model of atopic asthma: suppression by dexamethasone or antiinterleukin-5 antibody. Am J Respir Cell Mol Biol, 2000, Vol. 23(2): 241–246
[55] Cho JY, Miller M, Baek KJ, et al. Inhibition of airway remodeling in IL-5-deficient mice. J Clin Invest, 2004, Vol. 113(4): 551–560
[56] Huaux F, Liu T, McGarry B, et al. Eosinophils and T lymphocytes possess distinct roles inbleomycin-induced lung injury and fibrosis. J Immunol, 2003, Vol. 171(10): 5470–5481
[57] Mattes J, Yang M, Mahalingam S, et al. Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma. J Exp Med, 2002, Vol. 195(11): 1433–1444
[58] Sato M, Muragaki Y, Saika S, et al. Targeted disruption of TGF-β1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest, 2003, Vol. 112(10): 1486–1494
[59] Border WA, Noble NA, Yamamoto T, et al. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature, 1992, Vol. 360 (6402): 361–364
[60] Clouthier DE, Comerford SA, Hammer RE. Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK–TGF-β1 transgenic mice. J Clin Invest, 1997, Vol. 100(11): 2697–2713
[61] Sime PJ, Xing Z, Graham FL, et al. Adenovector-mediated gene transfer of active transforming growth factor-β1 induces prolonged severe fibrosis in rat lung. J Clin Invest, 1997, Vol. 100(4): 768–776
[62] Gorelik L, Flavell RA. Transforming growth factor-β in T-cell biology. Nature Rev Immunol, 2002, Vol. 2(1): 46–53
[63] Munger JS, Huang X, Kawakatsu H, et al. The integrin-αvβ6 binds and activates latent TGF-β1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell, 1999, Vol. 96(3): 319–328
[64] Roberts AB, Russo A, Felici A, et al. Smad3: a key player in pathogenetic mechanisms dependent on TGF-β. Ann NY Acad Sci, 2003, Vol. 995 (1): 1–10
[65] Flanders KC, Sullivan CD, Fujii M, et al. Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am J Pathol, 2002, Vol. 160(3): 1057–1068
[66] Khalil N, Corne S, Whitman C, et al. Plasmin regulates the activation of cell-associated latent TGF-β1 secreted by rat alveolar macrophages after in vivo bleomycin injury. Am J Respir Cell Mol Biol, 1996, Vol. 15(2): 252–259
[67] Ma LJ, Yang H, Gaspert A, et al. Transforming growth factor-β-dependent and -independent pathways of induction of tubulointerstitial fibrosis in β6–/– mice. Am J Pathol, 2003, Vol. 163(4): 1261–1273
[68] Ashcroft GS, Yang H, Glick AB, et al. Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nature Cell Biol, 1999, Vol. 1(5): 260–266
[69] Kaviratne M, Hesse M, Leusink M, et al. IL-13 activates a mechanism of liver fibrosis that is completely TGF-β independent. J Immunol, 2004, Vol. 173(6): 4020-4029
[70] Lee CG, Homer RJ, Zhu Z, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor β1. J Exp Med, 2001, Vol. 194(6): 809–821
[71] Lanone S, Zheng T, Zhu Z, et al. Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and –12 in IL-13-induced inflammation and remodeling. J Clin Invest, 2002,Vol. 110(4): 463–474
[72] Nakao A, Miike S, Hatano M, et al. Blockade of transforming growth factor-β/Smad signaling in T cells by overexpression of Smad7 enhances antigen-induced airway inflammation and airway reactivity. J Exp Med, 2000, Vol. 192(2): 151–158
[73] Hansen G, McIntire JJ, Yeung VP, et al. CD4+ T helper cells engineered to produce latent TGF-β1 reverse allergen-induced airway hyperreactivity and inflammation. J Clin Invest, 2000, Vol. 105(1): 61–70
[74] Kitani A, Fuss I, Naka mura K, et al. Transforming growth factor (TGF)- β1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-β1- mediated fibrosis. J Exp Med, 2003, Vol. 198(8): 1179–1188
[75] Kulkarni AB, Huh CG, Bexker D, et al. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA, 1993, Vol. 90(2): 770–774
[76] Smith RE, Strieter RM, Phan SH, et al. Production and function of murine macrophage inflammatory protein-1α in bleomycin-induced lung injury. J Immunol, 1994, Vol. 153(10): 4704–4712
[77] Smith RE, Strieter RM, Zhang K, et al. A role for CC chemokines in fibrotic lung disease. J Leukoc Biol, 1995, Vol. 57(5): 782–787
[78] Lloyd CM, Minto AW, Dorf ME, et al. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med, 1997, Vol. 185(7): 1371–1380
[79] Belperio JA, Keane MP, Burdick MD, et al. Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J Clin Invest, 2001, Vol. 108(4): 547–556
[80] Tokuda A, Itakura M, Onai N, et al. Pivotal role of CCR1-positive leukocytes in bleomycin-induced lung fibrosis in mice. J Immunol, 2000, Vol. 164(5): 2745–2751
[81] Blease K, Mehrad B, Standiford TJ, et al. Airway remodeling is absent in CCR1–/– mice during chronic fungal allergic airway disease. J Immunol, 2000, Vol. 165(3): 1564–1572
[82] Anders HJ, Vielhauer V, Frink M, et al. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Invest, 2002, Vol. 109(2): 251–259
[83] Moore BB, Paine R 3rd, Christensen PJ, et al. Protection from pulmonary fibrosis in the absence of CCR2 signaling. J Immunol, 2001, Vol. 167(8): 4368–4377
[84] Zhu Z, Ma B, Zheng T, et al. IL-13-induced chemokine responses in the lung: role of CCR2 in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol, 2002, Vol. 168(6): 2953–2962
[85] Gao JL, Wynn TA, Chang Y, et al. Impaired host defense, hematopoiesis, granulomatous inflammation and type 1/type 2 cytokine balance in mice lacking CC chemokine receptor 1. J Exp Med, 1997, Vol. 185(11): 1959–1968
[86] Ma B, Zhu Z, Homer RJ, et al. The C10/CCL6 chemokine and CCR1 play critical roles in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol, 2004, Vol. 172(3): 1872–1881
[87] Gordon S. Alternative activation of macrophages[J]. Nature Rev Immunol, 2003, 3(1): 23–35.
[88] Munder M, Eichmann K, Modolell M. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with TH1/TH2 phenotype. J Immunol, 1998, Vol. 160(11): 5347–5354
[89] Munder M, Eichmann K, Moran JM, et al. TH1/TH2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol, 1999, Vol. 163(7): 3771–3777
[90] Witte MB, Barbul A, Schick MA, et al. Upregulation of arginase expression in wound-derived fibroblasts. J Surg Res, 2002, Vol. 105(1): 35–42
[91] Zimmermann N, King NE, Laporte J, et al. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J Clin Invest, 2003, Vol. 111(12): 1863–1874
[92] Hogaboam CM, Gallinat CS, Bone-Larson C, et al. Collagen deposition in a non-fibrotic lung granuloma model after nitric oxide inhibition. Am J Pathol, 1998, Vol. 153(6): 1861–1872
[93] Numaguchi K, Eqashira K, Takemoto M, et al. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension, 1995, Vol. 26(6 Pt 1): 957–962
[94] Moore KW, de Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol, 2001, Vol. 19: 683–765
[95] Thompson K, Maltby J, Fallowfield J, et al. Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis. Hepatology, 1998, Vol. 28(6): 1597–1606
[96] Louis H, Van Laethem JL, Wu W, et al. Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice. Hepatology, 1998, Vol. 28(6): 1607–1615
[97] Arai T, Abe K, Matsuoka H, et al. Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo. Am J Physiol Lung Cell Mol Physiol, 2000, Vol. 278(5): L914–L922
[98] Demols A, Van Laethem JL, Quertinmont E, et al. Endogenous interleukin-10 modulates fibrosis and regeneration in experimental chronic pancreatitis. Am J Physiol Gastrointest Liver Physiol, 2002, Vol. 282(6): G1105–G1112
[99] Wangoo A, Laban C, Cook HT, et al. Interleukin-10- and corticosteroid-induced reduction in type I procollagen in a human ex vivo scar culture. Int J Exp Pathol, 1997, Vol. 78(1): 33–41
[100] Wang SC, Ohata M, Schrum L, et al. Expression of interleukin-10 by in vitro and in vivo activated hepatic stellate cells. J Biol Chem, 1998, Vol. 273(1): 302–308
[101] Nelson DR, Tu Z, Soldevila-Pico C, et al. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology, 2003, Vol. 38(4): 859–868
[102] Wynn TA, Cheever AW, Williams ME, et al. IL-10 regulates liver pathology in acute murine Schistosomiasis mansoni but is not required for immune down-modulation of chronic disease. J Immunol, 1998, Vol. 160(9): 4473–4480
[103] Hesse M, Piccirillo CA, Belkaid Y, et al. The pathogenesis of schistosomiasis is controlled by cooperating IL-10-producing innate effector and regulatory T cells. J Immunol, 2004, Vol. 172(5): 3157–3166
[104] Lee CG, Homer RJ, Cohn L, et al. Transgenic overexpression of interleukin (IL)-10 in the lung causes mucus metaplasia, tissue inflammation, and airway remodeling via IL-13-dependent and -independent pathways. J Biol Chem, 2002, Vol. 277(38): 35466–35474
[105] Taube C, Duez C, Cui ZH, et al. The role of IL-13 in established allergic airway disease. J Immunol, 2002, Vol. 169(11): 6482–6489
[106] Mattes J, Yang M, Siqueira A, et al. IL-13 induces airways hyperreactivity independently of the IL-4R α-chain in the allergic lung. J Immunol, 2001, Vol. 167(3): 1683–1692
[107] Feng N, Luqli SM, Schnyder B, et al. The interleukin-4/interleukin-13 receptor of human synovial fibroblasts: overexpression of the nonsignaling interleukin-13 receptor α2. Lab Invest, 1998, Vol. 78(5): 591–602
[108] Wood N, Whitters MJ, Jacobson BA, et al. Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor α2. J Exp Med, 2003, Vol. 197(6): 703–709
[109] Chiaramonte MG, Mentink-Kane M, Jacobson BA, et al. Regulation and function of the interleukin 13 receptor α2 during a T helper cell type 2- dominant immune response. J Exp Med, 2003, Vol. 197(6): 687–701
[110] Mentink-Kane MM, Cheever AW, Thompson RW, et al. IL-13 receptor α2 downmodulates granulomatous inflammation and prolongs host survival in schistosomiasis. Proc Natl Acad Sci USA, 2004, Vol. 101(2): 586–590
[111] Zheng T, Zhu Z, Liu W, et al. Cytokine regulation of IL-13Rα2 and IL-13Rα1 in vivo and in vitro. J Allergy Clin Immunol, 2003, Vol. 111(4): 720–728
[112] Jakubzick C, Choi ES, Kunkel SL, et al. Impact of interleukin-13 responsiveness on the synthetic and proliferative properties of TH1- and TH2-type pulmonary granuloma fibroblasts. Am J Pathol, 2003, Vol. 162(5): 1475–1486
[113] Daines MO, Hershey GK. A novel mechanism by which interferon-γ can regulate interleukin (IL)-13 responses. Evidence for intracellular stores of IL-13 receptor α-2 and their rapid mobilization by interferon-γ. J Biol Chem, 2002, Vol. 277(12): 10387–10393
[114] Wynn TA, Hesse M, Sandler NG, et al. P-selectin suppresses hepatic inflammation and fibrosis in mice by regulating interferon-γ and the IL-13 decoy receptor. Hepatology, 2004, Vol. 39(3): 676–687
[115] Clark JG, Dedon TF, Wayner EA, et al. Effects of interferon-γ on expression of cell surface receptors for collagen and deposition of newly synthesized collagen by cultured human lung fibroblasts. J Clin Invest, 1989, Vol. 83(5): 1505–1511
[116] Hansen G, Berry G, DeKruyff RH, et al. Allergen-specific TH1 cells fail to counterbalanceTH2 cellinduced airway hyperreactivity but cause severe airway inflammation. J Clin Invest, 1999, Vol. 103(2): 175–183
[117] Randolph DA, Stephens R, Carruthers CJ, et al. Cooperation between TH1 and TH2 cells in a murine model of eosinophilic airway inflammation. J Clin Invest, 1999, Vol. 104(8): 1021–1029
[118] Ford JG, Rennick D, Donaldson DD, et al. IL-13 and IFN-γ: interactions in lung inflammation. J Immunol, 2001, Vol. 167(3): 1769–1777
[119] Castro M, Chaplin DD, Walter MJ, et al. Could asthma be worsened by stimulating the T-helper type1 immune response? Am J Respir Cell Mol Biol, 2000, Vol. 22(2): 143–146
[120] Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science, 1998, Vol. 282(5397): 2258–2261
[121] Grunig G, Warnock M, Wakil AE, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science, 1998, Vol. 282(5397): 2261–2263
[122] Marth T, Strober W, Seder RA, et al. Regulation of transforming growth factor-β production by interleukin-12. Eur J Immunol, 1997, Vol. 27(5): 1213–1220
[123] Nelson DR, Lauwers GY, Lau JY, et al. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology, 2000, Vol. 118(4): 655–660
[124] Kaufman J, Sime PJ, Phipps RP. Expression of CD154 (CD40 ligand) by human lung fibroblasts: differential regulation by IFN-γ and IL-13, and implications for fibrosis. J Immunol, 2004, Vol. 172(3): 1862–1871
[125] Adawi A, Zhang Y, Baqqs R, et al. Blockade of CD40–CD40 ligand interactions protects against radiation-induced pulmonary inflammation and fibrosis. Clin Immunol Immunopathol, 1998, Vol. 89(3): 222–230
[126] Katsuma S, Nishi K, Taniqawara K, et al. Molecular monitoring of bleomycininduced pulmonary fibrosis by cDNA microarray-based gene expression profiling. Biochem Biophys Res Commun, 2001, Vol. 288(4): 747–751
[127] Kaminski N. Microarray analysis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol, 2003, Vol. 29(3 Suppl): S32–S36
[128] Anders RA, Yerian LM, Tretiakova M, et al. cDNA microarray analysis of macroregenerative and dysplastic nodules in end-stage hepatitis C virus-induced cirrhosis. Am J Pathol, 2003, Vol. 162(3): 991–1000
[129] Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature, 1996, Vol. 383(6603): 787–793
[1] Wynn TA. Fibrotic disease and the TH1/ TH2 paradigm. Nat Rev. Immunol, 2004, Vol. 4(8):583–594
[2] Sandler N G, Mentink-Kane M M, Cheever A, et al. Global gene expression profiles during acute pathogen-induced pulmonary inflammation reveal divergent roles for TH1 and TH2 responses in tissue repair. J Immunol, 2003, Vol. 171(7): 3655–3667
[3] Magalhaes A, Miranda DG, Miranda RG, et al. Cytokine profile associated with human chronic schistosomiasis mansoni. Mem Inst Oswaldo Cruz, 2004, Vol. 99(5 Suppl 1):21-26
[4] Mentink-Kane MM, Cheever AW, Thompson RW, et al. IL-13 receptor α2 downmodulates granulomatous inflammation and prolongs host survival in schistosomiasis. Proc Natl Acad Sci USA, 2004, Vol. 101(2): 586–590
[5] Chiaramonte M G, Cheever A W, Malley J D, et al. Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis. Hepatology, 2001, Vol. 34(2): 273–282
[6] Fulkerson PC, Fischetti CA, Hassman LM, et al. Persistent effects induced by IL-13 in the lung. Am J Respir Cell Mol Biol. 2006, Apr 27[Epub ahead of print]
[7] Oriente A, Fedarko NS, Pacocha SE, et al. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther, 2000, Vol. 292(3):988-994
[8] Fertin C, Nicolas JF, Gillery P, et al. Interleukin-4 stimulates collagen synthesis by normal and scleroderma fibroblasts in dermal equivalents. Cell Mol Biol, 1991, Vol. 37(8): 823–829
[9] Saito A, Okazaki H, Sugawara I, et al. Potential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro. Int Arch Allergy Immunol, 2003, Vol. 132(2): 168–176
[10] Walter DM, McIntire JJ, Berry G, et al. Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J Immunol, 2001, Vol. 167(8): 4668–4675
[11] Kumar RK, Herbert C, Yang M, et al. Role of interleukin-13 in eosinophil accumulation and airway remodelling in a mouse model of chronic asthma. Clin Exp Allergy, 2002, Vol. 32(7): 1104–1111
[12] Lee CG, Homer RJ, Zhu Z, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor β1. J Exp Med, 2001, Vol. 194(6): 809–821
[13] Lanone S, Zheng T, Zhu Z, et al. Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and –12 in IL-13-induced inflammation and remodeling. J Clin Invest,2002, Vol. 110(4): 463–474
[14] Kaviratne M, Hesse M, Leusink M, et al. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol, 2004, Vol. 173(6):4020-4029
[15] Liu T, Jin H, Ullenbruch M, et al. Regulation of found in inflammatory zone 1 expression in bleomycin-induced lung fibrosis: role of IL-4/IL-13 and mediation via STAT-6. J Immunol. 2004, Vol. 173(5):3425-3431
[16] Donnelly LE, Barnes PJ. Acidic mammalian chitinase--a potential target for asthma therapy. Trends Pharmacol Sci. 2004, Vol. 25(10):509-511
[17] Finkelman FD, Shea-Donohue T, Morris SC, et al. Interleukin-4 and interleukin-13-mediated host protection against intestinal nematode parasites. Immunol Rev, 2004, Vol. 201: 139-155
[18] Jinnin M, Ihn H, Yamane K, et al. Interleukin- 13 stimulates the transcription of the human alpha2(I) collagen gene in human dermal fibroblasts. J Biol Chem, 2004, Vol. 279(40):41783-41791
[19] Mentink-Kane MM, Wynn TA. Opposing roles for IL-13 and IL-13 receptor alpha 2 in health and disease. Immunol Rev, 2004, Vol. 202: 191-202
[20] Kaufman J, Sime P J, Phipps R P. Expression of CD154 (CD40 ligand) by human lung fibroblasts: differential regulation by IFN-γ and IL-13, and implications for fibrosis. J. Immunol, 2004, Vol. 172: 1862–1871